PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

EASL Congress 2024

5-8 June, Milan

N. Poster

Poster title

Applicant name

Status


LBP-002	GM-60106 (a peripheral 5HT2A antagonist) as a clinical candidate for metabolic dysfunction-associated steatohepatitis (MASH)	Jin Hee Ahn	Received

TOP-002	Validation of the gender-equity model for liver allocation (GEMA) in a nationwide cohort of liver transplant candidates in Spain	Mauel Luis Rodríguez-Perálvarez	Received

LBP-3	Semaglutide achieves resolution of metabolic dysfunction-associated steatohepatitis via modulation of multiple pathogenic pathways: insights from human and animal studies	Francisco Jácome-Blásquez	Received

TOP-003	Model for end-stage liver disease score-based liver allocation is associated with reduced survival in low donation countries – a comparative analysis between Germany and the USA	Leke Wiering	Received

TOP-004	Impact of MELD 3.0 on waitlist outcomes of metabolic dysfunction-associated steatohepatitis cirrhosis among liver transplant waitlist registrants	Margaret Teng	Received

LBP-005	Efficacy, safety, tolerability, and immunogenicity of JNJ-0535 following a reduction of viral antigen levels through administration of siRNA JNJ-3989 in patients with chronic HBeAg negative hepatitis B - interim data of the OSPREY study	Michael Biermer	Received

TOP-005	Immune checkpoint inhibitors after liver transplantation: the key role of immunosuppression management	Eleonora De Martin	Received

LBP-6	Efficacy of elafibranor in primary biliary cholangitis: results from the variable double-blind period of ELATIVE®, a randomised, placebo-controlled phase III trial	Costello Medical	Received

LBP-007	Beneficial effects of autologous macrophage therapy on clinical outcomes in patients with compensated cirrhosis: extended follow-up data from a randomized controlled Phase 2 trial	Paul Brennan	Received

SAT-007	Assessing sex differences in access to liver transplantation in Italy: a real-world nationwide study	Chiara Becchetti	Received

LBP-008	AAV8 gene therapy for mitochondrial neurogastrointestinal encephalomyopathy	Teresa Brevini	Received

FRI-8	Association of elevated liver biochemistries and clinical outcomes within strata of alkaline phosphatase levels in patients with primary biliary cholangitis	David W. Victor III	Received

THU-008	Does the use of liver frailty index in liver transplant assessment aid clinical decision making and correlate with patient outcomes?	Rachel Edwards	Received

SAT-008	Significance of routinely measured direct alcohol markers in long-term care after liver transplantation	Julia M. Grottenthaler	Received

WED-008	Adipose tissue as a predictor of morbidity and mortality in patients listed for liver transplantation	Maxence Lepour	Received

THU-009	Implementation of food insecurity screening within outpatient hepatology services: a clinical audit.	Rachel Howarth	Received

WED-009	CYTOMEGALOVIRUS SPECIFIC POLYFUNCTIONAL T-CELLS CONTROL CMV REACTIVATION, AFTER LIVER TRANSPLANTATION	ngela Carvalho Gomes	Received

SAT-009	Increased prevalence of metabolic-alcohol liver disease in Europe and of metabolic dysfunctionassociated steatotic liver disease in the Americas. Results of the global IMPROVEMENT study.	Luca Miele	Received

FRI-009	Diagnostic and prognostic performance of the LiverRisk score in tertiary care	Georg Semmler	Received

FRI-010	A non-invasive predictive model based on CT radiomics for hepatic venous pressure gradient in liver cirrhosis	Xu Guo	Received

SAT-10	Elaboration of a one-year mortality score for first elective liver transplantation recipients over 60 years based on the results of the french national cohort between 2007 and 2017	Marianne Latournerie	Received

LBP-010	Azemiglitazone in combination with GLP1 agonists increases benefit and could preserve lean body mass	Jerry Colca	Received

WED-010	Functions and molecular mechanisms of metformin in ameliorating ischemia-reperfusion injury of steatosis liver by inhibiting ferroptosis	Rong Li	Received

THU-010	Screening for liver disease in alcohol use disorder – is it worthwhile?	Marie Archibald	Received

LBP-011	Streamlined serodiagnosis of hepatitis delta: a novel lateral flow assay kit for on-site rapid diagnostics	Naranjargal Dashdorj	Received

SAT-011	Everolimus and de novo malignancies after liver transplantation in a nationwide french cohort study: an emulated target trial	Ilias Kounis	Received

LBP-012	Epidemiological trends and clinical impact of multidrug-resistant bacterial infections in patients with cirrhosis across Latin America: results from the ACLARA study	Juan Manuel Diaz	Received

TOP-012	Validation of transient elastography and the enhanced liver fibrosis test as prognostic biomarkers across the spectrum of steatotic liver disease	Nikolaj Torp	Received

LBP-13	Deciphering the role of mechanical forces in liver regeneration by a biomimetic liver regeneration chip	Yu Du	Received

SAT-013	Sequential normothermic regional and end-ischemic ex-situ machine perfusion allows the safe use of very old DCD donors in liver transplantation (DCDNet trial)	caterina martinelli	Received

FRI-014	Comparison of two ultrasound diagnostic systems for measuring liver stiffness in clinical practice	Simone Cappelli	Received

LBP-014	Enhancing prediction of moderate fibrosis in MASLD patients for Resmetirom treatment via machine learning	Winston Dunn	Received

SAT-014	Bariatric surgery post-liver transplantation: a Belgian nationwide study	Louis Onghena	Received

FRI-015	Stabilization of enhanced liver fibrosis and liver stiffness measures in the open-label extension of the phase 3 POISE trial of obeticholic acid for the treatment of primary biliary cholangitis	Sarah Robertson	Received

WED-015	Prognosticating hepatocellular carcinoma before and after liver transplantation with HepatoPredict	Joana Cardoso	Received

SAT-015	Screening for asymptomatic coronary artery disease in liver transplant recipients: is it time to replace stress echocardiography with coronary CT angiography in selected patients?	Chiara Manuli	Received

LBP-015	The effect of precursors on extracellular nicotinamide adenine dinucleotide in plasma	Sue Easaw	Received

THU-015	Feasibility of a digital lifestyle intervention (VITALISE) to support self-management in patients with metabolic dysfunction-associated steatotic liver disease	Hollie Smith	Received

SAT-016	Assessment of the role of liver transplantation with or without combined kidney transplantation in polycystic liver or liver and kidney disease	Claire Francoz	Received

LBP-16	Carvedilol versus propranolol in the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis	Jose Ignacio Fortea	Received

THU-016	A meta-ethnographic review of experiences and perceptions of physical activity and exercise in people with metabolic dysfunction-associated steatotic liver disease	Shelley Keating	Received

LBP-017	Liver-kidney crosstalk: the influence of hepatic oxalate release on kidney gluconeogenesis	Philipp Gabrys	Received

THU-017	Development of a nurse-led out-patient service to support earlier diagnosis and management of liver disease	Amy Thatcher	Received

FRI-017	Fibrosis activity versus disease stage: systemic markers of fibrosis activity have better prognostic performance than the liver biopsy in patients with alcohol-related liver disease	Stine Johansen	Received

SAT-017	QuantiFERON monitor as an immune function assay predictive of clinical events in liver transplant recipients: a validation study	Tess McClure	Received

FRI-018	Procalcitonin as a predictive marker of incident liver disease	Amanda Finnberg-Kim	Received

LBP-018	Promising first-in-human, first-in-class, Phase 1B immunogenicity data of VRON-0200, a novel checkpoint modifier containing immunotherapy, for HBV functional cure	EJ Gane	Received

SAT-018	Liver transplantation in cystic fibrosis: the evolving landscape in the United Kingdom	Georgeina Jarman	Received

LBP-019	Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B	Guofeng Cheng	Received

SAT-019	Recipient donor sex constellation differences in outcome after liver transplantation for hepatocellular carcinoma – an ELTR study	Christian Magyar	Received

FRI-020	Validation of FIB-6 Score in assessment of liver fibrosis in chronic hepatitis B	Khalid A Alswat	Received

LBP-020	A phase 1, double-blinded, randomized, placebo-controlled, multicenter global study evaluating the safety, tolerability, and antiviral activity of DF-006 in chronic hepatitis B, virologically-suppressed patients	Duyen Nguyen	Received

SAT-020	Evaluation of 18FDG-PET/CT for prediction of waitlist dropout and post transplantation recurrence in patients listed for hepato-cellular carcinoma	Catherine Lamarque	Received

THU-020	Evolution of health-related quality of life in liver transplantation patients in relation to acceptance and metabolic liver disease	Janne Suykens	Received

LBP-021	BRII-179 induced functional immune response, demonstrating potential to improve chronic hepatitis B functional cure	Qing Zhu	Received

SAT-021	Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival in an international multicentre cohort	Vincenzo Ronca	Received

THU-021	Outcomes from a nurse-led home-based care program for patients with liver cirrhosis	Catherine Yu	Received

FRI-021	An integrative machine learning method enhances postoperative liver failure risk assessment with preoperative indicators	Zongkun Zhang	Received

LBP-022	Preclinical safety data for PBGENE-HBV gene editing program supports advancement to clinical trials as a potentially curative treatment for chronic hepatitis B	Emily Harrison	Received

THU-022	Impact of a joint clinical nurse specialist and dietitian clinic on health related quality of life outcomes for patients with decompensated liver disease	Leah Cox	Received

WED-022	De novo malignancies after liver transplantation: a twenty years long-single center experience	Stefano Fonte	Received

FRI-022	N-terminal type III collagen propeptide, golgi protein 73 and their combination accurately assess siginificant and advanced fibrosis in chronic hepatitis B patients	Qianqian Chen	Received

SAT-022	Post-recurrence survival after liver transplantation for hepatocellular carcinoma: outcomes of an "orphan" disease	Marianna Maspero	Received

LBP-023	Targeting RuvBL1 hampers NASH-HCC progression by tipping the scale from mTOR-driven lipogenesis to AMPK-induced lipolysis	Alice Guida	Received

FRI-23	Effect of obeticholic acid on reduction and normalization of alanine aminotransferase and aspartate aminotransferase in the phase 3 POISE trial in primary biliary cholangitis	Robert G. Gish	Received

LBP-024	Performance of AASLD, AGA, AACE guidelines to identify patients for resmetirom treatment: pooled dataset including more than 4,000 patients with liver biopsy	Julie Dubourg	Received

SAT-24	Impact of ISO score on oncological outcomes and survival in HCC patients candidate for liver transplantation	Elisa Pinto	Received

LBP-025	Shortened telomeres impact liver regeneration in mice	Michael Hu	Received

LBP-026	Evidence of transplant benefit for patients with severe acute-on-chronic liver failure: Interim results of the CHANCE study	Anna Bosch	Received

SAT-026	Liver stiffness is associated with the results of long-term protocol biopsies in liver transplant patients recipients	Pauline RIVIERE	Received

FRI-026	Longitudinal association of magnetic resonance elastography with liver-related events and cardiovascular events in chronic hepatitis	Nobuharu Tamaki	Received

SAT-027	Women are also disadvantaged in accessing transplant outside the United States: analysis of the spanish liver transplantation registry	Marina Berenguer	Received

LBP-27	Combined effect of obeticholic acid and bezafibrate in patients with primary biliary cholangitis and inadequate response or intolerance to ursodeoxycholic acid: 6-month results from a phase 2 trial	Jennifer Lautenbach	Received

THU-027	A pilot pharmacist led carvedilol titration service leads to sustained doses of high dose carvedilol in patients with clinically significant portal hypertension	Yun Jung Kim	Received

FRI-027	Fibroblast activity kills - circulating endotrophin (PRO-C6) is prognostic for liver-related events in patients with cirrhosis from chronic hepatitis C	Thomas Wiggers	Received

WED-027	Long-term post-transplant emergence of metabolic syndrome is associated with gut microbial metabolites in urinary metabolomics	Jane Cox	Received

LBP-028	Effect of elafibranor on pruritus in primary biliary cholangitis: symptom severity and quality of life measurements from the phase III ELATIVE® trial	Costello Medical	Received

FRI-028	Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced chronic liver disease of mixed etiology	Giulia Francesca Manfredi	Received

THU-028	Usefulness of an educational activity through an informatic tool in participants with chronic hepatitis B infection	Judit Romero-Vico	Received

SAT-028	The relationship between spleen stiffness and portal hypertension liver transplant patients	Kanan Nuriyev	Received

SAT-029	Induction therapy using rabbit anti-thymoglobulin and IVIG for hyperimmunized liver transplant recipients	Nada Eldomiaty	Received

LBP-029	Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing Phase 3 study, MYR301	Pietro Lampertico	Received

FRI-029	Shear wave elastography predicts risk categories in patients with cirrhosis, PANDORA study	Jorge Poo	Received

THU-029	Nurse-led hepatocellular cancer surveillance in district general hospital	Kate Pingoy	Received

WED-029	Adipose-derived stem cell therapy enhances liver regeneration in echinococcus multilocularis infected mice through activation of the wnt/beta-catenin/nestin signaling axis	RENYONG LIN	Received

FRI-030	Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis-4 index stabilization in the phase 3 POISE trial of obeticholic acid for the treatment of primary biliary cholangitis	Alan Bonder	Received

LBP-030	Use of tocilizumab for the treatment of steroid and mycophenolate-refractory hepatitis and cholangiohepatitis induced by immune checkpoint inhibitor immunotherapy	Sophia Ling	Received

SAT-030	A visual classification scale of biliary anastomotic strictures with per-oral cholangioscopy predicts outcomes in liver transplant recipients	Andres Cardenas	Received

LBP-031	AZD2693, a potent PNPLA3 antisense oligonucleotide, decreases hepatic PNPLA3 mRNA and liver fat content in participants with presumed MASH and homozygous for the PNPLA3 148M risk allele	Javier Armisen	Received

SAT-031	Evolution of pre liver transplant cardiovascular risk factors and cardiac work-up: impact on post-transplant events	Margherita Saracco	Received

SAT-032	Risk stratification of emergent living donor liver transplantation from a nationwide survey of the Republic of Korea	Jongman Kim	Received

LBP-032	Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis – a subgroup analysis from the SELECT trial	Shazia Begum	Received

THU-032	"Ama il tuo Fegato" program: screening for hepatic fibrosis using liver stiffness measurement (LSM)	Paolo Scivetti	Received

LBP-033	Metabolic flux analysis using a 14C microtracer approach combined with accelerator mass spectrometry analysis - a proof of concept study on de novo lipogenesis	Martine Morrison	Received

THU-033	Early evaluation of a pharmacist-led clinic for the management of patients with chronic hepatitis B on antiviral treatment	Aya Al-Hasani	Received

FRI-033	Enhancing MRCP precision: a comprehensive analysis of intramuscular glucagon administration impact on biliary visualization	Fadi Abu Baker	Received

SAT-033	Three- vs. six-monthly measurement of phosphatidylethanol (PEth) in the detection of alcohol use relapse after liver transplantation (RAULT) for alcohol-associated liver disease (ALD)	Svetlana Adamcova Selcanova	Received

THU-034	Dietary composition in individuals with primary sclerosing cholangitis – high prevalence of inadequate fat-soluble vitamin intake	Catarina Lindqvist	Received

LBP-034	Evaluation of the PIKfyve kinase inhibitor Apilimod against hepatitis E virus infections	Julian Ring	Received

FRI-035	Development of a non-invasive machine learning-based model for predicting hepatic steatosis in patients with chronic hepatitis B	Zhiyi Zhang	Received

LBP-035	Luji-1 reduces fibrosis by blocking Neuroligin-4 and -neurexin and overexpressing thyroid hormone receptor-b, suggesting Rezdiffra sensitization and synergism in combination	Johnny Amer	Received

SAT-35	The yield of routine post-operative doppler ultrasound to detect early post-liver transplantation vascular complications	Iulia Minciuna	Received

LBP-36	Final results from the phase 3 REGENERATE trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis	Jennifer Lautenbach	Received

SAT-36	Impact of distance from liver transplant centre on outcomes following liver transplantation - an australian single centre study	Simone Chin	Received

SAT-037	Impact of recipient sex on long-term survival after liver transplantation in patients with high MELD	Laia Aceituno	Received

LBP-038	Expanding knowledge regarding real-world treatment of patients with primary biliary cholangitis with obeticholic acid from the Italian RECAPITULATE cohort	Francesca Terracciani	Received

FRI-038	Silver-coating of tunneled peritoneal drainage system is associated with a lower incidence of spontaneous bacterial peritonitis and device explanation	Sarah Lisa Schütte	Received

LBP-039	Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: Updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial	Simona Neuman	Received

FRI-039	Terlipressin therapy is associated with increased risk of colonization with multidrug-resistant bacteria in patients with decompensated cirrhosis	MARCUS MÜCKE	Received

THU-039	Educational intervention in cirrhotic outpatients with hepatic encephalopathy secondary to constipation	Martina Pérez Guasch	Received

FRI-040	Male sex is associated with worse outcomes in primary biliary cholangitis	Nirbaanjot Walia	Received

LBP-040	Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interim results for 2 years from the ASSURE study	Mary Standen	Received

THU-040	Establishment of the irish hepatology nurses association: an association for nurses working in liver disease in Ireland	Michèle Bourke	Received

SAT-040	Is there a need to screen for ischemic heart disease in liver transplant candidates without coronary calcification on routine chest CT?	Susan Fischer	Received

LBP-041	Screening and comparison of current clinical candidates in MASH using human 3D liver spheroids	Radina Kostadinova	Received

SAT-041	Real-world evidence of magnesium isoglycyrrhizinate for perioperative protection against hepatic injury in patients undergoing hepatectomy	Changzhen Shang	Received

FRI-041	Evaluating the influence of human albumin infusions on the MELD and MELD-Na scores in patients hospitalized with an acute decompensation of cirrhosis: an ATTIRE trial analysis	Nikolaj Torp	Received

SAT-042	A HDL-based prognostic model performs better than MELD in chronic liver failure	Rudolf E. Stauber	Received

LBP-042	First-in-human clinical result of a novel HBV-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma (HCC)	Karin Wisskirchen	Received

FRI-042	Comparison of clinical outcomes among patients with refractory ascites and implantation of either Alfapump®, tunneled peritoneal drainage system or transjugular intrahepatic portosystemic shunt	Sarah Lisa Schütte	Received

FRI-043	A multi-center randomized controlled study of primary prevention of esophageal variceal bleeding in cirrhotic patients treated with HVPG-guided therapy or standard heart rate-guided therapy: an interim analysis of the PORTHOS trial	Annelotte Broekhoven	Received

LBP-043	A phase 1, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of AHB-137 in Chinese healthy volunteers and subjects with chronic hepatitis B	Guofeng Cheng	Received

LBP-044	Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10,000 IU/mL: part 2 of the REEF-D study	Michael Biermer	Received

THU-044	Global subjective assessment and global leadership initiative on malnutrition as predictors of mortality in patients with cirrhosis	Vittoria Zambon Azevedo	Received

FRI-044	Impact of underlying etiology of liver cirrhosis on tests for diagnosing minimal hepatic encephalopathy	Julius Egge	Received

THU-045	Medicines optimisation in patients admitted with hepatic encephalopathy in UK centres	Arron Jones	Received

FRI-045	Superior prognostic accuracy of the LiverPRO score versus FIB-4 in predicting liver-related events in a cohort of 457,152 individuals	Katrine Prier Lindvig	Received

SAT-045	Outcome of simultaneous heart and liver transplants with HCC: analysis of US national database	Prasun Jalal	Received

LBP-045	Efficacy and safety of HSK31679, a thyroid hormone receptor ß agonist, for the treatment of asian nonalcoholic fatty liver disease: a multicenter randomized, double-blind, placebo-controlled, phase 2a trial	Feng Xue	Received

FRI-046	Alfapump implantation significantly improved quality of life and showed similar safety outcomes compared to a contemporaneously enrolled refractory ascites cohort	Jasmohan Bajaj	Received

LBP-46	A phase IIa basket clinical trial of allogeneic CD362-enriched umbilical cord-derived mesenchymal stromal cells (ORBCEL-CTM) in patients with primary sclerosing cholangitis and autoimmune hepatitis	Julian Yeh	Received

SAT-046	Detection of conventional adenomas and serrated lesions during repetitive colonoscopies after orthotopic liver transplantation	Christoph Schramm	Received

THU-046	Exploring the feasibility of ultrasound liver imaging reporting and data system (US LI-RADS) and visualisation score in clinical application	Dorothy Seng	Received

FRI-047	Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)	Enrico Pompili	Received

LBP-047	Development and validation of CLDQ-MASH: a disease specific health related quality of life instrument for patients with metabolic dysfunction-associated steatohepatitis (MASH)	Carey Escheik	Received

SAT-047	Racial disparities in the receipt of liver transplantation among african american patients with hepatocellular carcinoma in the United States: a systematic review	Nabil El Hage Chehade	Received

LBP-048	Preclinical proof of concept and discovery of siRNA therapeutics targeting CIDEB for metabolic dysfunction-associated steatohepatitis	Jianhua Zhang	Received

SAT-048	Long-term mortality and risk factors associated with mortality after liver transplantation in the modern era	Magdalena Meszaros	Received

SAT-49	Everolimus and hepatocellular carcinoma recurrence post liver transplantation: insights from an emulated target trial	Ilias Kounis	Received

THU-050	Urinary biomarkers of tubular and glomerular damage predict renal recovery in patients with hepatorenal syndrome-acute kidney injury	Salvatore Piano	Received

SAT-050	Liver transplantation for biliary tract cancer in primary sclerosing cholangitis	Christina Villard	Received

FRI-051	Differences between urgent and elective major surgery in patients with advanced chronic liver disease and discriminatory capacity of the VOCAL-Penn	Lidia Canillas Alavés	Received

SAT-051	The clinical relevance of prior bariatric surgery in alcohol-related liver disease in a nationwide belgian liver transplant population	Sander Lefere	Received

THU-052	Therapeutic plasma-exchange improves short-term survival in patients with ACLF admitted to intensive care unit with organ failures - a multinational AARC data analysis	Rakhi Maiwall	Received

SAT-052	Artificial intelligence and liver transplantation: post-transplantation chronic kidney disease prediction	PAUL CARRIER	Received

FRI-052	Anthropometric muscle mass indicators are effective in diagnosing muscle mass loss but are unable to diagnose myosteatosis, thus failing to identify all patients with sarcopenia in liver cirrhosis	Alexandra Alexopoulou	Received

SAT-053	Liver transplantation in patients with autoimmune hepatitis: a large single-center study	Mohssen NassiriToosi	Received

THU-053	Longitudinal salivary metagenomics in acute-on-chronic liver failure patients	Xavier Raffoux	Received

FRI-053	Wide variations in proton pump inhibitor use in hospitalized patients with cirrhosis in a worldwide cohort shows little impact on clinically significant outcomes	Jasmohan Bajaj	Received

SAT-054	Impact of lymphadenectomy for patients with clinically node-negative intrahepatic cholangiocarcinoma: a retrospective cohort study	Meng Sha	Received

THU-055	Differential impact of proton pump inhibitors, statins, and non-selective beta-blockers on survival in different stages of chronic liver disease	Wenyi Gu	Received

SAT-055	Post-colectomy liver transplant recipients have higher rates of chronic kidney disease at 1-year	Victoria Tatiana Kronsten	Received

FRI-55	Outcomes of minimal ascites in patients with etiologically controlled liver cirrhosis	Haiyu Wang	Received

WED-055	Effect of long-term treatment with Simvastatin and Rifaximin in mitochondrial and proinflammatory pathways in patients with decompensated cirrhosis. A single-cell RNA seq analysis in PBMCs	Adrià Juanola	Received

SAT-056	Long-term survival (=20 years) after liver transplantation in Italy: a single center retrospective experience	Maria Francesca Donato	Received

THU-056	Soluble PD-L1 levels as predictors of ACLF in decompensated cirrhosis: findings from two independent cohorts	Adrià Juanola	Received

WED-056	Activated cytotoxic T-cells in mesenteric lymph nodes limit systemic bacterial dissemination, inflammation, and disease progression in chronic liver injury	Pinky Juneja	Received

FRI-056	Clinical impact of acute kidney disease in patients with decompensated cirrhosis: insights from a prospective observational study on renal dysfunction	Alberto Calleri	Received

SAT-057	Poor radiological – histopathological concordance in patients transplanted for hepatocellular carcinoma: a single centre experience	Mzamo Mbelle	Received

WED-057	Exercise alters immune cell senescence and inflammation in cirrhosis patients with sarcopenia	PREETI NEGI	Received

FRI-057	End of life care in advanced chronic liver disease: results from a national audit of practice in the United Kingdom	Daniel Maggs	Received

THU-057	Distinguishing clinical profiles in acute-on-chronic liver failure: a comparative analysis of alcohol-related hepatitis versus infection precipitated acute-on-chronic liver failure	Annarein Kerbert	Received

FRI-058	Smoking cessation correlates with rapid decrease of inflammatory markers in patients with decompensated cirrhosis	Letitia Toma	Received

SAT-058	The survival benefit of liver transplantation for metabolic dysfunction associated steatotic liver disease: an Italian liver transplant registry study	Alessandro Vitale	Received

WED-058	High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension	Rajni Yadav	Received

WED-059	Effects of albumin treatment on cell death markers in patients with decompensated cirrhosis and in acute-on-chronic liver failure	Eugenio Rosado	Received

SAT-059	Retrospective population study of liver transplantation in Iceland – An update	Bjarki Leó Snorrason	Received

FRI-059	Proton pump inhibitors are not associated with an increased risk of hepatic encephalopathy	Simon Johannes Gairing	Received

THU-059	Therapeutic plasma exchange improves organ function and potentially increases short-term survival in ACLF-3 patients who do not respond to standard medical treatment: a single centre propensity score-matched retrospective study	Jonas Schumacher	Received

SAT-060	Needle tract seeding of hepatocellular carcinoma after liver transplantation: a single center experience	Chiara Sicuro	Received

THU-060	Lower inpatient mortality and second infections in inpatients with cirrhosis managed between 2021-22 than between 2011-13 in prospective North American cohorts	Jasmohan Bajaj	Received

WED-060	Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release during spontaneous bacterial peritonitis	Michael Rooney	Received

TOP-061	Whole blood thrombin generation improves the understanding of cirrhotic coagulopathy and predicts clinical outcomes in patients with cirrhosis: a prospective cohort study	Alberto Zanetto	Received

TOP-062	Global epidemiology of acute kidney injury in hospitalized patients with cirrhosis: the ICA-GLOBAL AKI study	Kavish Patidar	Received

TOP-063	The efficacy of Glucagon-like Peptide-1 receptor agonists in patients with compensated cirrhosis and obesity	Yee Hui Yeo	Received

TOP-064	Impact of bacterial infections on kidney function and survival in patients with decompensated cirrhosis and acute kidney injury worldwide – analysis of the ICA-GLOBAL AKI study	Adrià Juanola	Received

TOP-65	Outcomes of thromboelastography guided versus routine empirical or on-demand platelet transfusion in patients with liver cirrhosis and severe thrombocytopenia undergoing high-risk invasive percutaneous and vascular procedures: an open-label, randomized co	Sagnik Biswas	Received

TOP-066	Development and validation of a prognostic model (AMMON-AD) to define risk of overt hepatic encephalopathy in cirrhosis patients with acute decompensation	María Pilar Ballester	Received

FRI-067	Impact of Farnesoid X receptor polymorphisms on prognosis in hepatocellular carcinoma	Talha Ozudogru	Received

THU-067	Predictors of clinical response to empirical antibiotic therapy in patients with cirrhosis and bacterial infections: results from a resource-constrained setting	Chitta Ranjan Khatua	Received

FRI-068	Predictors of clinical trajectories in patients surviving an acute decompensation of cirrhosis	Carmine Gambino	Received

THU-068	Predicting with the "POAD" score the course of acute kidney injury in acute-on-chronic liver failure: a metabolomics approach	Rakhi Maiwall	Received

WED-068	Cell-free DNA dynamics in advanced cirrhosis: unravelling the role of nuclear and mitochondrial DNA in inflammation, coagulation dysfunction and short-term mortality	Marilena Stamouli	Received

SAT-068	Accuracy of spleen stiffness measurement for the diagnosis of high-risk esophageal varices in patients with advanced chronic liver disease: a systematic review and individual patient data meta-analysis	Elton Dajti	Received

THU-069	Serum bile acids determine AKI progression and terlipressin non-response in patients with acute-on-chronic liver failure with acute kidney injury	Rakhi Maiwall	Received

FRI-069	Rifaximin monotherapy has significantly reduced the risk of overt hepatic encephalopathy recurrence versus lactulose monotherapy in patients with cirrhosis and a history of previous episode(s): a post hoc analysis of randomized trials	Jasmohan Bajaj	Received

SAT-069	Effects of zibotentan and dapagliflozin on patients with compensated cirrhosis: a randomized double-blind placebo controlled exploratory pilot study	Jan Oscarsson	Received

WED-069	Bone morphogenic protein 9 (BMP9): a novel therapeutic agent for the prevention of extrahepatic organ failure in acute-on-chronic liver failure (ACLF)	Alexandra Phillips	Received

THU-070	Dynamic assessment of lactate and AARC-Laclear score could determine survival in acute-on-chronic liver failure with septic shock admitted to the intensive care unit: a prospective cohort study [NCT06116305]	Vishnu Girish	Received

FRI-070	Prevalence of dysgeusia in patients with advanced chronic liver disease, relationship with the liver-disease progression status, and impact on malnutrition-sarcopenia-frailty	Marina Cipullo	Received

WED-070	Isolation and immortalization of human endothelial cells from the portal vein	Aina Anton	Received

SAT-070	Argon plasma coagulation or endoscopic band ligation for gastric antral vascular ectasia: a randomized comparative analysis	Ashok Jhajharia	Received

THU-071	Impact of underlying portal hypertension and systemic inflammation on acute-on-chronic liver failure (ACLF) severity and outcome	Vlad Taru	Received

WED-071	The association of hepatocyte large extracellular vesicles with plasma biomarkers levels improve prediction of mortality in patients with cirrhosis	audrey Payancé	Received

TOP-072	Red blood cell distribution width-to-platelet ratio estimates the 3-year risk of decompensation in patients with metabolic dysfunction-associated steatotic liver disease-related cirrhosis	Mario Romeo	Received

TOP-073	Extensive characterization of new biomarkers associated with infection and outcome of decompensation of cirrhosis using high throughput metabolomics, lipidomics and cytokinomics	Cristina López-Vicario	Received

WED-074	The role of endothelial FoxO1 pathway in decompensated liver cirrhosis and acute-on-chronic liver failure	Fabian Schachteli	Received

THU-074	Effect of terlipressin on patients with hepatorenal syndrome, alcohol-associated hepatitis, and acute-on-chronic liver failure grade 0–2	Vanessa Borkhoche	Received

SAT-074	Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension. A randomized, double-blind clinical trial	Valeria Perez-Campuzano	Received

FRI-074	Rifaximin reduces healthcare utilization but not overall costs in patients with cirrhosis and recurrent episodes of hepatic encephalopathy: a retrospective efficacy study	Diederick van Doorn	Received

SAT-075	Hemodynamic alterations and survival outcomes in cirrhotic patients with cirrhotic cardiomyopathy undergoing transjugular intrahepatic portosystemic shunt	Yaozu Liu	Received

WED-075	Exploring the immunomodulatory potential of TLR7/8 agonism in decompensated cirrhosis	Dimitrios Patseas	Received

THU-075	Incidence and prognostic value of zinc and selenium deficiency in cirrhosis	Nina Dominik	Received

FRI-075	The lower, the worse? Impact of PHES results on the risk of overt hepatic encephalopathy in patients with minimal hepatic encephalopathy	Christian Labenz	Received

SAT-076	Patients with hepatorenal syndrome and lower baseline mean arterial pressure derive significant survival benefit from treatment with terlipressin	Vanessa Borkhoche	Received

WED-076	Increased gut urease activity contributes to hyperammonemia and is a potential biomarker of disease severity in cirrhosis	DEEPIKA JAKHAR	Received

FRI-076	Physical frailty diagnosed by short physical performance battery test is an independent poor prognostic factor of 360-day mortality in patients with liver cirrhosis	Alexandra Alexopoulou	Received

THU-076	Machine learning algorithms predict survival in patients with cirrhosis hospitalized due to infections based on routine features obtained within 24 hours of addmision	Shoham Dabbah	Received

SAT-077	Prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt by live combined Bifidobacterium and Lactobacillus tablets: a randomized controlled trial	Ying Li	Received

WED-077	APASL-ACLF without previous decompensation is rare but immunological distinct from ACLF with previous decompensation in a european cohort	Mona-May Langer	Received

THU-077	Prognostic value of nutritional index in patients with decompensated cirrhosis: a single-center cohort study	Heechul Nam	Received

FRI-077	Cirrhotic liver transplant candidates with portosystemic shunts benefit from low dietary soluble fiber consumption	Simona Parisse	Received

SAT-78	Prospective 5-year follow-up study of spleen stiffness measurement with a spleen-dedicated module (SSM@100Hz) for predicting hepatic decompensation in cACLD: competitive risk analysis	Luigi Colecchia	Received

FRI-078	Long-term albumin administration in outpatients with decompensated cirrhosis and diabetes mellitus: post-hoc analysis of the ANSWER trial database	Giulia Iannone	Received

WED-078	Systemic albumin administration improves the gut microbiome and intestinal permeability in animal models of cirrhosis and ACLF	Alexandra Phillips	Received

THU-079	Pre-transplant work-up for acute-on-chronic liver failure patients in intensive care units, a nationwide french survey	Claire BELLEC	Received

WED-080	Hepatic inflammation-senescence-regeneration gene expression during recovery from ACLF and the effect of granulocyte-colony stimulating factor (GCSF), toll-like receptor-4 (TAK-242) inhibition and their combination (G-TAK)	MohammadMahdi Saeidinejad	Received

THU-080	The predictive role of immunoglobulins indicative of gut barrier dysfunction in a prospective patient cohort with cirrhosis and acute decompensation	David Tornai	Received

FRI-080	Hypodynamic cardiocirculatory status measured at echocardiography is associated with one-month mortality in patients admitted for acute decompensation of liver cirrhosis	Alexandru Victor Dragan	Received

SAT-080	Residual minimal ascites 3 months after TIPS implantation indicates risk of further decompensation and death	Lukas Hartl	Received

FRI-081	Lisinopril is associated with reduced hepatocellular carcinoma and mortality risk in patients with MASLD-related compensated cirrhosis: a multicenter, nationwide propensity score matching analysis	Yee Hui Yeo	Received

WED-081	Carvedilol decreases hepatic vascular resistance in cirrhosis by deactivating hepatic stellate cells (HSC) and improving liver sinusoidal endothelial cells (LSEC) dysfunction, resulting in decreased liver fibrosis and improved nitric oxide release	Yeldos Nulan	Received

SAT-81	Association between alleviation of portal vein thrombosis and mortality rate in cirrhotic patients: a prospective cohort study	Xiaoquan Huang	Received

FRI-082	Unveiling the role of GH-IGF1 axis in decompensated cirrhosis: implications for sarcopenia, frailty, decompensations, and mortality	Parminder Kaur	Received

WED-082	Multifactorial modulation of the endothelial transcription factor ERG in chronic liver disease	Eric Felli	Received

SAT-82	A Phase 2 study of OCE-205, a novel, selective vasopressin receptor mixed agonist-antagonist: positive proof-of-concept established in subjects with cirrhosis and hepatorenal syndromeacute kidney injury (HRS-AKI)	Agnella Matic	Received

THU-082	A clinical decision support tool to identify predictors of decompensation, acute-on-chronic liver failure and mortality in liver cirrhosis from the multi-center SingHealth chronic liver disease registry (SoLiDaRity-DAM)	Jason Chang	Received

THU-083	Acute kidney injury (AKI) severity in critically-ill patients with decompensated liver cirrhosis and acute-on-chronic liver failure (ACLF)	Lena Wolters	Received

WED-083	Multi-compartment metabolomics for stratifying cirrhotic patients with acute decompensation	Christophe Junot	Received

FRI-83	The impact of acute kidney injury in cirrhosis: a meta-analysis of 5,202,232 patients	Vasileios Lekakis	Received

SAT-083	Changes in mean arterial pressure are inadequate to guide treatment with terlipressin and albumin in patients with hepatorenal syndrome – acute kidney injury	Valeria Calvino	Received

TOP-084	Galectin 9 predicts clinical outcome and regulates immune dysfunction in acute-on-chronic liver failure	Antonio Riva	Received

TOP-085	Final results from the italian real-world experience on lusutrombopag treatment in cirrhotic patients with severe thrombocytopenia: insights from the reality study	Paolo Gallo	Received

WED-086	Nicotinamide riboside supplementation improves bacterial clearance and mitigates fibrosis in animal model of cirrhosis	NIDHI NAUTIYAL	Received

FRI-086	Untargeted serum metabolomic profiles remain stable over time in large multi-center cohort of >700 outpatients with cirrhosis	Jasmohan Bajaj	Received

SAT-086	Assessment of portal hypertension risk by liver and spleen stiffness using real-time 2D-shear wave elastography – the prospective AiXplore study	David Bauer	Received

THU-086	Proton pump inhibitors does not impact on the severity and mortality of the acute-on-chronic liver failure: andalusian multicentric prospective study	María del Carmen García Gavilán	Received

WED-087	Exploring the potential of human serum albumin to reprogram B cell function	Berta Romero-Grimaldo	Received

THU-087	Herpesvirus viremia – cause or consequence of ACLF? Higher prevalence of cytomegalovirus, Epstein–Barr virus and herpes simplex virus viremia in patients with acute-on-chronic liver failure	Jannik Sonnenberg	Received

SAT-087	The presence of NOD2 risk variants is associated to a higher incidence of first decompensation in patients with cirrhosis and varices	Henrik Karbannek	Received

WED-088	Enhancing infection diagnostics and antimicrobial resistance detection in cirrhosis: a clinical metagenomics approach for blood culture assessment	Merianne Mohamad	Received

SAT-088	Safety and Efficacy of the Natriuretic Peptide Ularitide in Refractory Cirrhotic Ascites: Interim Analysis of a Randomized Controlled Trial	Rasmus Gantzel	Received

THU-088	Blood and peritoneal metabolomics suggest VS-01 actively captures metabolites associated with acute-on-chronic liver failure	Berenice Alard	Received

FRI-088	Patterns & predictors of postacute discharge location other than home in a global cohort of 3,678 patients hospitalized with cirrhosis	Wai-Kay Seto	Received

THU-089	Bilirubin monoglucuronides play an important role in the pathophysiology of acute-on-chronic liver failure	Nahum Méndez-Sánchez	Received

SAT-089	Evaluating the correlation between portal pressure, collagen proportional area, and a-smooth muscle actin in patients with portal hypertension due to MASH cirrhosis	Pol Boudes	Received

WED-089	Characterising the hemodynamic and pro-inflammatory profile of a CCl4/LPS-induced acute-on-chronic liver failure (ACLF) rat model	Vlad Taru	Received

FRI-089	Infections and outcomes in patients hospitalized with an acute decompensation of cirrhosis: insights from the ATTIRE trial	Nikolaj Torp	Received

THU-090	Safety and efficacy of liver hemodialysis in managing hepatic dysfunction: a systematic review and meta-analysis	Eyad Gadour	Received

FRI-090	New concept of cirrhosis recompensation in clinical practice: it´s key time	Ins Barreiros Coelho Rodrigues	Received

SAT-090	Improvement of liver frailty, hand grip strength and mid-upper arm circumference in cirrhotic patients after TIPS insertion	Martin Andreas Kabelitz	Received

WED-090	Developing a discovery platform for engineered macrophage cell therapies for end stage liver disease	Lara Campana	Received

THU-091	Predictors of acute-on-chronic liver failure (ACLF) and mortality in ambulatory cirrhotic patients	Maamoun Basheer	Received

FRI-092	Thyroid and adrenal dysfunction is associated with negative mid-term prognosis in decompensated cirrhosis	Laura Iliescu	Received

WED-092	Hyperuricemia leads to early cognitive dysfunction and neuronal cell injury in bile-duct ligated rats	hristopher F. Rose	Received

SAT-092	The Toulouse algorithm identifies patients with an increased risk of cardiac decompensation only in patients with TIPS for refractory ascites	Emma Vanderschueren	Received

FRI-093	Clot wave analysis parameters are associated with the severity of liver cirrhosis	Kessarin Thanapirom	Received

THU-093	Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid	Antonio De Vincentis	Received

SAT-093	Sustainable endoscopy in hepatology: quantifying the effect of applying BAVENO VII guidelines on the endoscopic carbon footprint; a multi-centred regional assessment	Dylan Angel	Received

WED-094	Food antigen-specific antibodies contribute to hypergammaglobulinemia in patients with decompensated liver cirrhosis	Lara Kelsch	Received

THU-094	Clinical benefits with maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study	Douglas Mogul	Received

SAT-094	Mild overt hepatic encephalopathy (HE) – more than meets the eye	Chiara Mangini	Received

THU-095	Novel machine learning algorithm for risk prediction of cholangiocarcinoma in primary sclerosing cholangitis	Ewa Wunsch	Received

WED-95	Pharmacological inhibition of high mobility group box 1 ameliorate sepsis induced hepatic micro vascular dysfunction and portal hypertension in non-cirrhotic and cirrhotic animals	Vaibhav Tiwari	Received

SAT-095	Trial of the establishment of shear wave elastography measurement methods for improvement of versatility	Hidemi Unozawa	Received

TOP-096	Glucagon-like peptide-1 receptor agonist, semaglutide attenuates liver cirrhosis-related skeletal muscle atrophy in diabetic mice	Kosuke Kaji	Received

TOP-097	Dynamics of systemic inflammation after TIPS implantation and their impact on acute-on-chronic liver failure and liver-related death	Andrea Kornfehl	Received

THU-098	Appraising gain of an extended 2-year placebo-controlled trial in primary biliary cholangitis: challenges for evaluating clinical outcomes	Bettina E. Hansen	Received

FRI-098	Feasibility of bedside ultrasonography of rectus femoris muscle for sarcopenia diagnosis in liver cirrhosis	Sara De Monte	Received

WED-098	Low-density lipoprotein can predict hospital readmissions and outcomes following acute decompensation of cirrhosis	Kohilan Gananandan	Received

SAT-099	Splenic stiffness using spleen-dedicated 100 Hz transient elastography compared with the Baveno criteria to predict high risk esophageal varices in cirrhosis	Harsh Jain	Received

THU-099	Small duct primary sclerosing cholangitis is not associated with a heightened risk of colorectal cancer compared to inflammatory bowel disease alone	Sarah Al-Shakhshir	Received

FRI-099	Risk of serious infection in patients with chronic liver disease: a nationwide population-based cohort study	Won Sohn	Received

WED-99	Hyperammonemia-induced mitochondrial dysfunction is abrogated by targeting toll-like receptor 4	Supachaya Sriphoosanaphan	Received

FRI-100	Bleeding risk after endoscopic polypectomy in patients with cirrhosis	Christoph Schramm	Received

WED-100	Role of apoptosis in B-cell compartment retraction during decompensation of cirrhosis and acute-on-chronic liver failure	Lorena Paule	Received

SAT-100	Heart failure outcomes following transjugular intrahepatic portosystemic shunts	Jemima Finkel	Received

THU-100	Factors associated with the real-world biochemical response to fibrate therapy in primary biliary cholangitis	Maria van Hooff	Received

WED-101	Modulation of portal and hepatic venous flow leads to fibrotic liver changes and can be prevented through anticoagulation	Beat Moeckli	Received

SAT-101	Morphological changes in esophageal varices in patients with HCV related cirrhosis who achieved sustained virological response by direct-acting antivirals	Chikako Nagao	Received

THU-101	Non-invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis based on the cholestasis degree	Ciro Celsa	Received

FRI-101	Rectus femoris cross sectional area predicts 90-day readmission in patients hospitalized for an acute decompensation of cirrhosis	Roberta Gagliardi	Received

SAT-102	The safety and technical success of endoscopic ultrasound-guided portal pressure gradient measurement: a systematic review and meta-analysis	Yousaf Zafar	Received

THU-102	Specific glycomic profiles can identify patients at risk of poor transplant-free survival in primary biliary cholangitis	Nicky Somers	Received

FRI-103	Screening and assessing Sarcopenia in liver cirrhosis: feasibility and implications for clinical outcomes	Philipp Altmann	Received

THU-103	Results from a phase 2a trial with the CD80 antagonist RhuDex as a second line treatment for primary biliary cholangitis	Gideon Hirschfield	Received

THU-104	Familial risk of biliary tract cancer and colorectal cancer in patients with primary sclerosing cholangitis	Erik von Serh	Received

FRI-104	The respiratory assessment of cirrhotic patients: six-minute walk test is an independent predictor of mortality in cirrhosis	Onur Keskin	Received

WED-104	Loss of heterogeneity and CD4+ T-cell differentiation in patients with alcohol-related cirrhosis	Paola Zuluaga	Received

SAT-104	Impact of albumin dosing on the need for terlipressin therapy and prognosis in patients with liver cirrhosis	Eva Maria Schleicher	Received

THU-105	Improvement in lipid profiles with elafibranor treatment in primary biliary cholangitis during the phase III ELATIVE® trial	Costello Medical	Received

WED-105	Nitazoxanide directly protects from stress-induced cell death to alleviate liver damage in preclinical models of acute-on-chronic liver failure	Marie Gerard	Received

FRI-105	Tissue factor pathway inhibitor and serum amyloid A-4 protein are promising to predict occurrence of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt	Huan Tong	Received

SAT-105	Neutrophil extracellular traps are not linked to the development of decompensation, ACLF, or death in clinically stable patients with advanced chronic liver disease	Lorenz Balcar	Received

WED-106	Liver cirrhosis and epithelial damage – The gut-liver axis in spontaneous bacterial peritonitis and its modulation by p53	Celina Macek	Received

SAT-106	Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) predicts acute-on-chronic liver failure in patients with acute decompensation	Lorenz Balcar	Received

THU-106	Prospective european reference network registry (R-LIVER) supports improvement in bone disease care delivery at local level for patients with autoimmune liver diseases and enables detailed description of risk elements	Boglarka Bozso	Received

FRI-106	Change in frailty status with nutritional therapy in patients with cirrhosis – a randomized controlled trial	Sudhir Maharshi	Received

SAT-107	Assessment of the diagnostic accuracy of cell count on spontaneous bacterial peritonitis	Prebashan Moodley	Received

THU-107	Short- and medium-term effects of hypnosis and psychoeducational interventions on fatigue associated with primary biliary cholangitis: a randomized controlled trial	Christophe Corpechot	Received

WED-107	Administration of xyloglucan alone or in combination with norfloxacin improves intestinal barrier homeostasis in cirrhotic rats with ascites	Ramon Bartolí	Received

FRI-107	Folic acid prescription is associated with a lower mortality and hospital readmission in patients with decompensated alcohol-related liver cirrhosis	Laura Buttler	Received

TOP-108	Evaluation of the scoring systems dedicated to liver transplantation in acute-on-chronic liver failure (ACLF) in an international multicenter cohort	Sébastien LHermite	Received

WED-109	Evaluation of statins as a new therapy to alleviate hepatic encephalopathy in cirrhotic mice	Subas Aroob	Received

FRI-109	Differences in the clinical phenotype of decompensated liver cirrhosis between MASLD, MetALD and ALD patients	Laura Buttler	Received

THU-109	Increasing prevalence of primary biliary cholangitis in The Netherlands	Rozanne de Veer	Received

THU-110	Time to initiation of the second-line therapy obeticholic acid in patients with primary biliary cholangitis	Sonal Kumar	Received

WED-110	Alterations in plasma neuronal and glial proteins in varying severities of cirrhosis and differing grades of hepatic encephalopathy	Marilena Stamouli	Received

FRI-110	Safety and effectiveness of anticoagulation in patients with cirrhosis listed for liver transplantation: a single center observational study	Riccardo Caccia	Received

THU-111	Second-line treatment in recurrent primary biliary cholangitis after liver transplantation: an international multicentre study	Nadir Abbas	Received

WED-111	Plasma proteomics uncovers progression markers of acute-on-chronic liver failure	Florian Rosenberger	Received

SAT-111	Lower levels of Insulin-like growth factor 1 are independently associated with unfavorable prognosis in patients with advanced chronic liver disease	Michael Schwarz	Received

FRI-112	Rapid infection diagnostics in liver disease– evaluation of a multiplex PCR platform to improve infection and antimicrobial resistance detection	veena ramachandran	Received

THU-112	Quantitative magnetic resonance cholangiopancreatography provides additional prognostic value in prediction of transplant-free survival in primary sclerosing cholangitis	Tim Middelburg	Received

WED-112	Plasma extracellular vesicles improve prediction of 90 day mortality in patients with acute decompensation of cirrhosis	Shantha VALAINATHAN	Received

THU-113	Optimizing thiopurine therapy in autoimmune hepatitis (AIH): a multi-center study on monitoring metabolite profiles and co-therapy with allopurinol	Jan Philipp Weltzsch	Received

SAT-113	Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites	Antonino Lombardo	Received

FRI-113	Diagnostic scoring system for diagnosis of covert hepatic encephalopathy in child-pugh class a cirrhosis patients	MASANORI FUKUSHIMA	Received

WED-113	Histological, molecular, and neuromotor alterations of the liver-brain axis in an aged model of experimental cirrhosis	Oriol Juanola	Received

WED-114	In vivo experiments and network pharmacology to explore the effect and mechanism of JiGuCao capsule in treating liver cirrhosis	Shihao Zheng	Received

SAT-114	Heartbeats and Platelets: unveiling the symphony of heart failure and congestive hepatopathy	Anas Zaher	Received

THU-114	Alkaline phosphatase levels at 6 months as a predictor of response to ursodeoxycholic acid at 1 year in patients with primary biliary cholangitis	Carmen Sendra	Received

FRI-114	Entecavir can significantly improve the prognosis of patients with first decompensated hepatitis B cirrhosis	Rui Ding	Received

THU-115	Ursodeoxycholic acid treatment for primary sclerosing cholangitis	Bregje Mol	Received

FRI-115	Validation of an easy-to-use malnutrition screening in cirrhosis to predict outcome	Stefan Fürst	Received

SAT-116	Association between pre-operative TIPS and post-operative mortality in a veterans affairs cohort	Nadim Mahmud	Received

FRI-116	Prognostic significance of HDL-associated apolipoproteins in patients with decompensated cirrhosis and spontaneous bacterial peritonitis	Mohamad Murad	Received

WED-116	Primary biliary cholangitis increases the risk of hepatocellular carcinoma: results from Mendelian randomization analysis and bioinformatics analysis	Yikai Wang	Received

THU-116	The skin microbiome diversity differs in regard to age and gender but not presence of pruritus in patients with hepatobiliary diseases	Miriam M. Düll	Received

THU-117	The course of radiological features and liver stiffness measurement during long-term treatment with fibrates and UDCA in patients with Primary Sclerosing Cholangitis	Elisa Catanzaro	Received

WED-117	Targeted breath biopsy® profiling of induced biomarkers unveils a metabolic adaptation in cirrhosis toward alcohol production	Giuseppe Ferrandino	Received

SAT-117	Evaluation of Baveno VII criteria and other non-invasive tests for clinically significant portal hypertension in chronic hepatitis D	Mathias Jachs	Received

FRI-117	Acute kidney injury and infections as the main determinants of outcome in hospitalised patients with liver cirrhosis: a retrospective cohort from a tertiary hospital	Adonis Protopapas	Received

WED-118	Mitoquinol intervention ameliorates cirrhosis associated hematopoietic imbalance and improves innate immune function	Deepanshu Maheshwari	Received

SAT-118	Ongoing alcohol use after TIPS implantation is associated with increased rates of ACLF and liver related death among individuals with alcohol related ACLD	Caroline Schwarz	Received

THU-118	Prophylaxis for tuberculosis and pneumocystis jirovecii does not seem necessary in patients with autoimmune hepatitis treated with corticosteroid therapy: spanish multicentre study	ALVARO DIAZ-GONZALEZ	Received

FRI-118	Independent association of loss of skeletal muscle mass with long-term liver-related mortality in cirrhotic patients	Jiarui Zheng	Received

THU-119	Seladelpar treatment increases fatty acid beta-oxidation and serum carnitine levels in patients with primary biliary cholangitis consistent with increased expression of the carnitine transporter OCTN2 and the mitochondrial carnitine shuttle	Yun-Jung Choi	Received

SAT-119	Frequency of chronic liver disease after chemotherapy for gastrointestinal tumors	Paulo Bittencourt	Received

FRI-119	Role of HLA DR+ CD4+ T cell %T cell in mediating the effect of Lactobacillus delbrueckii on liver cirrhosis	Ningning Zhang	Received

THU-120	The impact of ursodeoxycholic acid on biochemistry of patients with primary biliary cholangitis in a nationwide cohort	Ellen Werner	Received

WED-120	Albumin infusion in decompensated cirrhotic patients with ascites induced decreasing serum active form of vitamin D, 1,25 dihydroxy vitamin D, an opposite effect on promoting systemic inflammatory cytokines reduction	Thitaporn Roongrawee	Received

FRI-120	Impact of diabetes mellitus on results in the animal naming test in patients with and without liver cirrhosis	Eva Maria Schleicher	Received

FRI-121	Safety and tolerability of long-term albumin treatment in patients with decompensated cirrhosis	Eugenio Rosado	Received

WED-121	Increased procoagulant activity of tissue factor-expressing microvesicles in patients with liver cirrhosis	Adonis Protopapas	Received

THU-121	Harnessing synergy of ´triple´ anti-cholestatic therapy in patients with primary biliary cholangitis	Guilherme Canado	Received

SAT-121	Point-of-care ultrasound of the inferior vena cava for intravascular volume assessment in patients with cirrhosis during intravenous albumin infusion	Daniel Segna	Received

FRI-122	Decompensated cirrhosis is associated with disruption of nuclear positioning in skeletal muscle and selective atrophy of type II myofibers	Aldo J Montano-Loza	Received

THU-122	Patient-reported insights on current care practices for primary biliary cholangitis, quality of life and self-management: results of the german PBC online survey	Diane Langenbacher	Received

SAT-122	Biomarkers of extracellular matrix remodelling are linked to portal hypertension and disease progression in patients with stable advanced chronic liver disease	Benedikt Simbrunner	Received

WED-122	The soluble guanylate cyclase pathway is dysregulated in rodent models of cirrhosis and portal hypertension	Thomas Sorz-Nechay	Received

THU-123	External validation of the international autoimmune hepatitis group response criteria in a multicentric real-world cohort	Lorenz Grossar	Received

SAT-123	Evaluation of portal hemodynamics after etiological factor removal and persistence of varices in patients with an HVPG <10mmHg and NITs within the grey zone	Virginia Hernández-Gea	Received

FRI-123	Measuring the burden and impact of comorbidity in cirrhosis: insights from clinical database analysis	Lynsey Corless	Received

WED-123	Female mice with cirrhosis are more prone to acute and chronic effects of psilocybin exposure without tolerance compared to male mice	Jasmohan Bajaj	Received

FRI-124	Upper extremity skeletal muscle index to assess sarcopenia in patients with cirrhosis	Anna Ostrovskaya	Received

THU-124	Population pharmacokinetics of elafibranor in healthy participants and patients with liver diseases: A pooled analysis of 17 clinical studies	Costello Medical	Received

WED-124	Assessment of plasma VCAM-1 levels in pediatric portal hypertension and its relationship with disease severity	huihong yu	Received

SAT-124	Lower post-transjugular intrahepatic portosystemic shunt overt hepatic encephalopathy and mortality in patients with hepatic venous communication	Li Ma	Received

THU-125	Key questions that patients with primary biliary cholangitis should ask their physician -Delphi method-	Ellen Werner	Received

WED-125	Differential regulation of soluble guanylate cyclase signaling during liver fibrosis regression	Thomas Sorz-Nechay	Received

FRI-125	Recompensation after TIPS reduces the risk of hepatocellular carcinoma and death in patients with decompensated cirrhosis	José Sánchez Serrano	Received

SAT-125	Comparison of endoscopic variceal ligation and endoscopic cyanoacrylate injection for the treatment of acute variceal bleeding from the cardia to the lesser curvature of the stomach	Yu-Fu Chen	Received

WED-126	Biglycan as a biomarker in acute-on-chronic liver failure (ACLF)	Martin Schulz	Received

THU-126	Metabolomic signature in autoimmune hepatitis discriminates disease activity and predicts response to treatment	Kalliopi Zachou	Received

FRI-126	Impact of micronutrient deficiencies on the mortality of patients with cirrhosis admitted for acute decompensation	Ariadna Altadill	Received

THU-127	Effects of HLA-G in primary biliary cholangitis: a study on a genetic isolate population	Michela Miglianti	Received

FRI-127	The relationship between abnormal body composition by computed tomography imaging and long-term mortality in patients with cirrhosis	Rui Huang	Received

SAT-128	Circulating fibronectin levels are linked to endothelial dysfunction, fibrogenesis, and portal hypertension in advanced chronic liver disease	Benedikt Simbrunner	Received

THU-128	A randomized phase II proof-of-concept study of beta-lapachone in patients with primary sclerosing cholangitis	Hans Jeong	Received

FRI-128	Usefulness of liver volume assessment for simple screening of covert hepatic encephalopathy	MASANORI FUKUSHIMA	Received

THU-129	Maralixibat improves growth in patients with progressive familial intrahepatic cholestasis: data from the MARCH/MARCH-ON trials	Jolan Terner-Rosenthal	Received

SAT-129	Role of serum Mac-2 binding protein glycosylation isomer in identifying patients with chronic liver diseases at risk for portal hypertension-related complications	Kessarin Thanapirom	Received

FRI-129	Construction and validation of a nomogram prediction model for predicting cirrhosis-related deaths based on severe sarcopenia and clinical serological indicators	Hong Yu	Received

WED-129	Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: a multicenter retrospective case-control study	LAURE ELKRIEF	Received

WED-130	Prevalence and predictors of porto-sinusoidal vascular disorder in patients with persistent and unexplained gamma-glutamyl transferase elevation: a multicenter study	Nicola Pugliese	Received

SAT-130	Three-dimensional transjugular intrahepatic portosystemic shunt geometry predicts shunt dysfunction in decompensated liver cirrhosis	Markus Kimmann	Received

FRI-130	Pre- and post-test diagnostic concordance rates of TJLB for suspected liver and blood diseases	Asako Nogami	Received

THU-130	The role of transient elastography and enhanced liver fibrosis score in IgG4–hepato-pancreato-biliary related disease	Rodrigo Motta	Received

THU-131	Rifaximin helps reduce cholestasis in patients with primary biliary cholangitis and increased fecal calprotectin	Laura Iliescu	Received

SAT-131	End-procedural complete hemodynamic response may not be essential for the clinical success of tips in patients with cirrhosis	Valentina Adotti	Received

FRI-131	Effect of adipose-related parameters on survival in patients with cirrhosis: a systematic review and meta-analysis	Xinxing Tantai	Received

WED-131	Von Willebrand factor antigen reflects portal hypertension severity in porto-sinusoidal vascular disorder and predicts liver-related outcomes	Lorenz Balcar	Received

WED-132	Role of transient elastography in diagnosis and prognosis of Fontan-associated liver disease	Marta Cuadros	Received

THU-132	Obeticholic acid normalizes inflammatory biomarkers in patients with primary biliary cholangitis	David E. Jones	Received

FRI-132	Spontaneous bacterial empyema is a rare yet life-threatening complication in patients with hepatic hydrothorax	Grace Wong	Received

THU-133	Radiomics for prognostication in primary sclerosing cholangitis: a proof-of-concept using GLRLM run entropy	Laura Cristoferi	Received

FRI-133	Decreasing incidence of cirrhosis due to hepatitis C following the treatment as prevention for hepatitis C nationwide elimination campaign	Einar Stefan Bjornsson	Received

WED-133	Quality of life in adults with Wilson disease: a study from the international Wilson disease registry	Camille Omar Kamlin	Received

FRI-134	Six years long-lasting clinical benefits of previous short-term resistance training in cirrhosis – follow-up after a clinical randomized trial	Luise Aamann	Received

SAT-134	Paired assessment of the hepatic venous pressure gradient with the push-wedge versus balloon-occlusion technique: impact of intrahepatic collaterals	Naomi Gestels	Received

THU-134	Metabolomic signature by 1H-NMR spectroscopy discriminates autoimmune hepatitis from other liver diseases	Kalliopi Zachou	Received

WED-134	Treatment adherence and associated clinical outcomes for Wilson disease patients: a real-world, retrospective, multinational survey	Niall Hatchell	Received

FRI-135	Von Willebrand factor is associated with portal vein thrombosis in patients with liver cirrhosis	Yuzheng Zhuge	Received

THU-135	Real-world study of reasons for non-utilization of second-line treatment in patients with primary biliary cholangitis	Costello Medical	Received

SAT-135	Soluble urokinase plasminogen activator receptor (suPAR) levels predict survival in patients with portal hypertension undergoing TIPS	Sven Loosen	Received

WED-135	Impact of metabolic alterations on liver phenotype of patients with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ)	Christina Schrader	Received

SAT-136	The modified child-turcotte-pugh score based on plasma ammonia to predict survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt: a multicenter validation	Feng Zhang	Received

THU-136	The epidemiological and prognostic burden of autoimmune liver disease: results of a nationwide population-based study over the past decade	Christophe Corpechot	Received

WED-136	Comorbidity burden associated with fatigue or pruritus in patients with primary biliary cholangitis in the United States: a matched case-control study	Sonal Kumar	Received

FRI-136	Aspirin reduces risk of ascites and encephalopathy in cirrhotic patients without increasing the risk of gastrointestinal bleeding	Roie Tzadok	Received

THU-137	Ulcerative colitis-associated anti-integrin aV6 antibodies are highly prevalent in primary sclerosing cholangitis	Moritz Leppkes	Received

SAT-137	Multivariable models for prediction of decompensation in compensated advanced chronic liver disease often lack external validation and measures of calibration	Vincent HAGHNEJAD	Received

WED-137	Reviewing the largest experience of liver transplantation for Wilson´s disease in the UK: single centre review of patient and graft outcomes and long term survival	James Liu Yin	Received

WED-138	Patients with alpha-1-antitrypsin deficiency and the risk of developing liver events: a longitudinal cohort study	Pavel Strnad	Received

THU-138	The male-to-female ratio among patients with primary biliary cholangitis depends on age	Ellen Werner	Received

TOP-139	Combination of liver steatosis and premenopausal is a risk factor for DILI due to cyclin-dependent kinase 4/6 inhibitors as first-line treatment for metastatic breast cancer	Mar Riveiro Barciela	Received

TOP-140	Evolution of clinical presentation, treatment and prognosis of patients with alveolar echinococcosis treated at the university hospital Zurich: a 50-year experience	Ansgar Deibel	Received

TOP-141	Longitudinal assessment of individuals with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ genotype) provides evidence for clinical patient management	Malin Fromme	Received

TOP-142	Safety and efficacy of direct oral anticoagulants in cirrhotic and non-cirrhotic splanchnic vein thrombosis	Lucia Giuli	Received

TOP-143	Porto-sinusoidal vascular disease among patients undergoing surgery for liver metastases: prevalence, non-invasive diagnosis, and burden on surgical outcomes	Elton Dajti	Received

TOP-144	Heterozygosity for rare Apolipoprotein B variants predispose to severe metabolic associated steatotic liver disease	Matteo Mureddu	Received

TOP-145	p.Pro871Arg variant in JAG1 demonstrates a common manifestation of Alagille´s syndrome	Preeti Sharma	Received

TOP-146	Activation of the HIF-1alpha pathway in cholangiocytes of patients with biliary atresia and its association with cilia disruption	Patricia Quelhas	Received

TOP-147	Long-term, real-world outcomes under obeticholic acid treatment in primary biliary cholangitis: a nationwide multicentre study	Nadir Abbas	Received

TOP-148	Interleukin-2 mediated regulatory T cell expansion is associated with dual outcomes of ductular reaction and liver fibrosis	Man Chun Wong	Received

TOP-149	Plasmatic expression of miR122-5p and miR21-5p predicts relapse of autoimmune hepatitis after treatment withdrawal	Pinelopi Arvaniti	Received

TOP-150	Molecular analysis of checkpoint inhibitor-induced liver injury	Sarp Uzun	Received

THU-151	A prospective study on the causes of notable elevation of alanine aminotransferase (ALT) as well as elevation of both ALT and alkaline phosphatase (ALP) with special emphasis on drug-induced liver injury (DILI)	Sigurdur Solvi Sigurdarson	Received

FRI-151	RNA editing for the treatment of Alpha-1 antitrypsin deficiency	Prashant Monian	Received

SAT-151	The role of interleukin-8 in primary sclerosing cholangitis-associated immune cell dysregulation	Lander Heyerick	Received

WED-151	Routine cholestasis genetic testing in patients with intrahepatic cholestasis of pregnancy reveals high prevalence of genetic variants of bile acid transport defects	Naim Alkhouri	Received

WED-152	Design and study population of MITIGATE: the first multinational randomized controlled clinical trial in IgG4 related disease, evaluating the efficacy and safety of the CD19 B cell depleting agent inebilizumab	Emma Culver	Received

THU-152	Liver fibrosis in adolescents and young adults with autoimmune hepatitis: magnetic resonance elastography, transient elastography and liver fibrosis changes during transition of care	Maciej Janik	Received

SAT-152	The deletion of PTP1B protects against liver biliary damage by shitting immune cell recruitment and enhancing oval cell proliferation	Silvia Calero Pérez	Received

FRI-152	Gene editing to treat liver metabolic disorders: harnessing paired Cas9-Nickases for efficient and safe treatment of primary hyperoxaluria type 1	Laura Torella	Received

WED-153	Advances in the diagnosis of cholestatic liver diseases with the implementation of exome sequencing	Ignasi Olivas	Received

THU-153	Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in primary biliary cholangitis	Giulia Francesca Manfredi	Received

SAT-153	Single-cell RNA sequencing identifies the fundamental role of intrahepatic CD8+ T cells in the pathogenesis of autoimmune hepatitis	Ignasi Olivas	Received

FRI-153	High prevalence of steatotic liver disease and systemic inflammation in hereditary fructose intolerance (HFI) patients independent of age, BMI and the presence of metabolic syndrome	Teresa Cardoso Delgado	Received

FRI-154	Copper overload promotes steatosis in Wilson disease by inhibiting peroxisome proliferator activated receptor alpha - fatty acid binding protein 1- glutathione peroxidase 4 signaling and inducing ferroptosis	Chen Liang	Received

THU-154	Diabetes mellitus (DM) is associated with worse outcomes in patients with primary biliary cholangitis (PBC) regardless of the presence of liver steatosis: results from the ColHai registry	María Del Barrio Azaceta	Received

WED-154	Evaluation of secondary sarcopenia and Fontan circulatory failure in post-Fontan hepatic complications	Yohei Koizumi	Received

SAT-154	Studying cholangiocyte properties and functions using a bile duct on a chip	Henry Hoyle	Received

FRI-155	Introduction of class I-III mutations of CFTR in isogenic human iPSCs-derived cholangiocytes and 3D organoids provides pathophysiological information relevant for treatment of cystic fibrosis-related liver disease (CFLD)	Romina Fiorotto	Received

SAT-155	Impaired hepatic sympathetic neuronal communication intensifies hepatic inflammation, fibrosis and metabolic dysregulation, exacerbating liver injury	sadam BHat	Received

WED-155	A ratio of exchangeable copper below 15% accurately excludes Wilson disease and may be useful for the first-line ethiologic work-up within a liver unit	Zoe Mariño	Received

THU-155	Incidence of fungal and other opportunistic infections in patients with autoimmune hepatitis: a spanish multicentre study	Alvaro Diaz-Gonzalez	Received

TOP-156	SRT-015: Novel therapeutic for cholestatic liver diseases	Kathleen Elias	Received

TOP-157	Risk of extrahepatic malignancies in patients with autoimmune hepatitis: a nationwide cohort study	Sung Won Chung	Received

WED-158	Disease experience and care expectations in european patients with immune-mediated liver disease	Pierre-Antoine Soret	Received

THU-158	Improvements in serum bile acid levels are associated with improvements in key markers of liver health after maralixibat treatment in children with progressive familial intrahepatic cholestasis: data from the MARCH/MARCH-ON trials	Jolan Terner-Rosenthal	Received

SAT-158	Machine learning-driven identification of serum protein signature for primary sclerosing cholangitis and enhanced liver fibrosis score	Ilan Vaknin	Received

FRI-158	The cyst microenvironment is spatially patterned to promote polycystic liver disease	Scott Waddell	Received

FRI-159	The whole genome sequence and transcriptome study on the HCCs derived from patients with Fontan-associated liver disease	Taiji Yamazoe	Received

WED-159	Usefulness of serological scores in the diagnosis of Fontan-associated liver disease	Marta Cuadros	Received

SAT-159	Mitochondrial integrity and auto(mito)phagy are disrupted in experimental models of primary biliary cholangitis, contributing to disease pathogenesis	Irune Lasa	Received

THU-159	Assessing the safety, tolerability and efficacy of rituximab in patients with difficult-to-treat autoimmune hepatitis: results from a tertiary UK liver unit	Abhishek Gairola	Received

THU-160	Long-term variability of pruritus in primary sclerosing cholangitis and implications for future clinical trial design	Amber Garrick	Received

WED-160	Autoantibody diagnostics in pediatric non-viral liver diseases: a multicenter retrospective head-to-head comparison of immunofluorescence- and enzyme-linked immunosorbent assay-based testing	Theresa Kirchner	Received

SAT-160	Lysophosphatidic acid (LPA)-receptors, a group of established itch receptors, show elevated agonism during cholestasis and are likely to contribute to cholestasis-associated itch	Frank Wolters	Received

WED-161	Liver steatosis and fibrosis in children with diabetes mellitus type 1: single-center analysis including MASLD-associated genetic variants	Wiktor Smyk	Received

THU-161	Hepatic sarcoidosis diagnosis and management: an italian multicenter study	Cristina Della Corte	Received

FRI-161	Correlation of non-invasive tests with histological features and intrahepatic Z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease	Zehrah Nanji	Received

SAT-161	Inhibition of bile acid conjugation improves DDC-induced cholestatic liver injury in mice with a humanized bile acid pool	Claudia Fuchs	Received

FRI-162	Analysis of cellular crosstalk in fibrocystic liver disease (PKHD1-/- mouse) reveals a central role for cholangiocytes, neutrophils and chronic biliary infection in disease pathogenesis	Mario Strazzabosco	Received

WED-162	Performance of transient elastography, Fib4 and APRI in the diagnosis of severe liver fibrosis in patient with HFE hemochromatosis	Edouard Bardou-Jacquet	Received

THU-162	Lack of association between persistently raised serum transaminase levels and hepatic steatosis/steatohepatitis in autoimmune hepatitis (AIH)	Sarah Flatley	Received

SAT-163	Spatial characteristics of cell compartments in primary sclerosing cholangitis	Markus Jördens	Received

THU-163	Single-cell RNA sequencing of autoimmune hepatitis identifies pathogenic marker MIF and reveals distinctions between CD8-Tc-PDCD1 cells in autoimmunity and cancer	Chao Cai	Received

WED-163	Non-invasive testing reveals fibrosis risk in heterozygous Alpha-1 Antitrypsin deficiency	George Marek	Received

FRI-163	Pronounced vasculature phenotypes in new mouse models with ALGS and BA-associated mutations in Jag1	Anna Maria Frontino	Received

THU-164	Evaluation of four chatbots in autoimmune liver disease: a comparative analysis	Jimmy Daza	Received

SAT-164	Mice lacking the NO receptor develop primary sclerosing cholangitis	Muhammad Ashfaq-Khan	Received

WED-164	Interim safety results of the ongoing international phase I/II GATEWAY gene therapy trial with VTX-801 conducted in adult patients with Wilson disease	bernard benichou	Received

FRI-164	Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease	Zehrah Nanji	Received

THU-165	Risk of primary sclerosing cholangitis is increased among patients with gastritis – a nationwide cohort study	Lina Lindström	Received

SAT-165	Impaired muscle metabolism during exercise is associated with elevated IL-6 in PBC patients with fatigue: is this a new therapeutic target?	Aaron Wetten	Received

WED-165	Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6 months of givosiran treatment in a subgroup analysis of the phase 3 ENVISION study	Holly Hunter	Received

FRI-165	SarsCov2 vaccine does not increase the risk of autoimmune liver disease	Stanislas Pol	Received

WED-166	Efficacy and safety of odevixibat in a subgroup of adult patients with progressive familial intrahepatic cholestasis in the PEDFIC 2 study	Paris Fossa	Received

THU-166	Portal hypertension and its prognostic implications in patients with autoimmune hepatitis	Lukas Burghart	Received

FRI-166	Impaired nuclear glycogen metabolism affects liver homeostasis in Argininosuccinic aciduria	Leandro Soria	Received

SAT-166	Functional relevance of CD44 for hepatocyte proliferation in diet-induced liver injury models	Sophia Bernatik	Received

THU-167	Diagnostic and therapeutic trends in primary biliary cholangitis: insights from the european reference network registry (R-LIVER)	Alessio Gerussi	Received

FRI-167	Modelling wolman disease using genetically engineered human liver organoids	Davide Selvestrel	Received

SAT-167	Generation and utilisation of an advanced iPSC-derived hepatocyte model for cholestasis modelling	Elena Garitta	Received

TOP-168	Urgent call to action: people living with primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD) lose 10 years of life compared to those with IBD alone	Kristel Leung	Received

TOP-169	Sex, ethnicity and clinical outcomes in autoimmune hepatitis: results from a large multicenter longitudinal cohort	Aldo J Montano-Loza	Received

THU-170	Paris II criteria are better than Poise to predict liver-related complications after second line therapy in patients with primary biliary cholangitis	HELENA HERNANDEZ-EVOLE	Received

SAT-170	Establishing a cholangioid library for biliary niche-on-a-chip multicellular models for the study of liver disease-associated ductular reaction	Tian Lan	Received

WED-170	TRISTAN- Retrospective real world data in management of Wilson disease therapies in Germany	Verena Aliane	Received

FRI-170	Impact of helminth infection on the efficacy of COVID-19 mRNA vaccine in mice	Jinpeng Su	Received

FRI-171	Paediatric solid organ transplant recipients (SOTR) demonstrate greater serological response to initial SARS-CoV-2 vaccination than adult SOTR, and comparable rates of antibody degradation	María Pilar Ballester	Received

SAT-171	Advancements in liver biopsy analysis: convolutional neural networks for portal tract segmentation	Giorgio Cazzaniga	Received

WED-171	Spleen stiffness and VWF-based non-invasive tests reflect severity of prehepatic and presinusoidal portal hypertension	Lorenz Balcar	Received

WED-172	Transaminase Pattern Over Time Is Not Associated with a More Aggressive Hepatic Evolution: Results from the AEEH Wilson Registry.	Marina Berenguer	Received

FRI-172	Primary adult hepatocytes-derived organoids to characterize intrahepatic cholestasis	Benedetta Blarasin	Received

THU-172	Investigating ACOX2 deficiency as an underlying cause of recurrent hypertransaminasemia in the Spanish population: an epidemiological study	MARTA ALONSO-PEÑA	Received

WED-173	Clinical, radiological and demographic characteristics of a female cohort of polycystic liver disease patients from the United Kingdom	Avisnata Das	Received

FRI-173	Mutational profile and correlation with Leipzig score in Wilson disease - a comprehensive analysis	Anand Kulkarni	Received

SAT-173	TAZ and YAP play an interdependent role in biliary development and adaptation to cholestasis	Adelya Gabdulkhakova	Received

THU-173	Predicting post-partum flare in Autoimmune Hepatitis- who is at risk?	Charlotte Sewell	Received

WED-174	Next-generation sequencing for non-cirrhotic portal thrombosis and its impact on portal hypertension	Ilias Kounis	Received

SAT-174	Expression of inflammatory markers in cholangiocyte organoids from patients with primary sclerosing cholangitis recapitulate disease severity	Philip Puchas	Received

THU-174	Assessment of the pharmacokinetic drug-drug interaction potential of elafibranor with atorvastatin in healthy adult male participants: an open-label phase I trial	Costello Medical	Received

FRI-174	Spectrum of UGT1A1 variations in chinese patients with Gilbert´s syndrome	Wenting Tan	Received

THU-175	Clinical outcome in patients with autoimmune hepatitis and its variant with primary sclerosing cholangitis	Karolina Wronka	Received

SAT-175	PPAR-delta activation with seladelpar regulates cholangiocyte inflammation	Xia Wu	Received

WED-175	Intrauterine blood transfusion causes dose- and time-dependent signal alterations in the liver and the spleen on fetal magnetic resonance imaging	Michael Schwarz	Received

THU-176	Chronic pruritus presents with similar clinical features in metabolic and cholestatic liver diseases	Miriam M. Düll	Received

SAT-176	Itg-Cre/DTA mice develop the autoimmune biliary disease that serologically and pathogenically models human primary biliary cholangitis	Jiaqi Zhang	Received

WED-177	Determination of liver biopsy quality criteria for the diagnosis of porto-sinusoidal vascular disorder (PSVD)	Chloé De Broucker	Received

SAT-177	Assessment of PPARdelta target engagement in mouse liver assessed by single nuclei sequencing following a single oral dose of seladelpar.	Edward Cable	Received

THU-177	Patient-reported outcomes in primary sclerosing cholangitis: an australian multicentre cohort perspective	Natassia Tan	Received

THU-178	Understanding the experience of people living with primary biliary cholangitis (PBC): further development of an experience map	Costello Medical	Received

SAT-178	Galectin-3 and prohibitin 1 are autoantigens in IgG4-related cholangitis without clear-cut protective effects against toxic bile acids	David Trampert	Received

WED-178	Enhanced liver phenotyping in unexplained chronic liver disease: the LIPHE algorithm	Anna Sessa	Received

SAT-179	A DNA methylation signature associated with inflammation is found in primary sclerosing cholangitis and IgG4-related cholangitis	Rodrigo Motta	Received

WED-179	Liver fibrosis status and circulating polymers in alpha-1 antitrypsin deficiency patients with a Z/rare genotype	Naomi Kappe	Received

THU-179	Pruritus in primary biliary cholangitis: exploring the itch phenomenon and its progression	Marcin Krawczyk	Received

WED-180	Clinical profile and outcomes of Wilson´s disease in the young and adult population	Anand Kulkarni	Received

SAT-180	Targeting neutrophil injury-pathways and fibrogenesis in non-parenchymal immune tissue-like liver organoids generated from human induced pluripotent stem cells	Susanna Quach	Received

SAT-181	WTAP deficiency in mice hepatocyte induces cholestatic liver diseases by modulating nuclear receptor FXR	Chuanhui Peng	Received

THU-181	Sleep disturbance due to pruritus is associated with anxiety, depression, and worse quality of life: evidence for management of pruritus and sleep in chronic liver disease	Anna Halliday	Received

WED-181	Use of metallothionein 1 as an ancillary tool for the diagnosis of Wilson disease	Clàudia Garcia-Solà	Received

THU-182	Acute liver injury with autoimmune features following SARS-CoV-2 vaccination in an ERN/IAIHG cohort: autoimmune hepatitis versus drug-induced autoimmune-like hepatitis	Benedetta Terziroli Beretta-Piccoli	Received

SAT-182	Immunokinetics of CD4+ T cells in primary sclerosing cholangitis by functional transcriptome analysis.Immunokinetics of CD4+ T cells in primary sclerosing cholangitis by functional transcriptome analysis	Mayu Ouchi	Received

WED-182	The enhanced liver fibrosis test in alpha-1 antitrypsin deficiency patients homozygous for the Z-allele	Naomi Kappe	Received

SAT-183	Moderate overexpression of c-Met in hepatocytes decreases cholestatic liver injury	Aránzazu Sánchez	Received

WED-183	Neurodegeneration in aceruloplasminemia and carriers of heterozygous ceruloplasmin variants: brain atrophy or iron toxicity?	Marlene Panzer	Received

THU-183	Immunosuppressive treatment facilitates hepatic recompensation in patients with decompensated cirrhosis due to autoimmune hepatitis – a pilot study	Benedikt Hofer	Received

SAT-184	Primary biliary cholangitis symptoms are reduced in liver specific Mcpip1 knock-out mice after treatment with probiotic lactobacillus rharmnosus	Katarzyna Trzos	Received

THU-184	Fatigue is not influenced by chronotype and is reported to be mainly muscular in patients with primary biliary cholangitis	Erica Nicola Lynch	Received

WED-184	Evaluation of routine outpatient assessment methods for post-Fontan procedure liver complications	Yohei Koizumi	Received

SAT-185	Human leukocyte antigen-DRB1 expression in cholangiocytes of ´early´ primary sclerosing cholangitis	Ynto de Boer	Received

THU-185	Second line therapy in patients with primary biliary cholangitis and inadequate response to UDCA: are we choosing the right target population for clinical trials?	Alejandra Villamil	Received

WED-185	Frequency of ATP8B1, ABCB11 and ABCB4 gene mutations in adult patients with idiopathic chronic cholestasis	Paulo Bittencourt	Received

THU-186	Long term risk assessment of patients with primary sclerosing cholangitis using clinical prognosis models	Matei Mandea	Received

WED-186	Exchangeable copper quantification fells below normal range in a high proportion of patients with Wilson disease during follow-up	Zoe Mariño	Received

THU-187	Landscape of gall bladder cancers in India: a 25 years experience at a tertiary care cancer centre	RUPAL TRIPATHI	Received

WED-187	Clinical and biochemical characteristics of a Danish and Turkish cohort of incident and prevalent patients with primary biliary cholangitis	Hasan Eruzun	Received

WED-188	Diagnosis and monitoring pathways using non-invasive tests in patients with alpha-1 antitrypsin deficiency-associated liver disease: results from an expert Delphi panel	Virginia C. Clark	Received

THU-188	Hydroxychloroquine as an adjuvant drug to immunosuppressive treatment to achieve histological remission in autoimmune hepatitis	Andreia Evangelista	Received

THU-189	Optimization of treatment in patients with primary biliary cholangitis: Gamma-glutamyl transferase levels as an early prognostic marker for ursodeoxycholic acid response. Results from the ColHai registry	Flor María Fernández-Gordón Sánchez	Received

WED-189	Patient survey of Wilsons disease patients in the United Kingdom	William Griffiths	Received

THU-190	Quantitative assessment of anti-mitochondrial antibodies in primary biliary cholangitis: a cross-sectional analysis	Lorenzo Canova	Received

WED-190	Elevated hepatic copper content in porto-sinusoidal-vascular disorder: leading down a wrong track	Lorenz Balcar	Received

WED-191	The impact on adherence and patient satisfaction following a switch to trientine tetrahydrochloride for the maintenance therapy in Wilson´s disease	Fabio Tedone	Received

THU-192	Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis	Carlo Saitta	Received

WED-192	Raising awareness of long term chelation therapy challenges in Wilson´s disease - Potential implications of monitoring and developing skin and vascular complications	James Liu Yin	Received

TOP-193	Consumption of a mediterranean diet with high-polyphenol content extra-virgin olive oil (EVOO) in patients with MASLD: effects on clinical parameters and gene expression on peripheral blood mononuclear cells (PBMCs)	Lydia Giannitrapani	Received

WED-194	Diagnostic performance of non-invasive tests and comparison of AGA and EASL algorithm for the screening of MASLD-related advanced fibrosis in diabetes and nutrition clinics	Cyrielle Caussy	Received

SAT-194	Effect of statin therapy in patients with obesity and cirrhosis secondary to metabolic dysfunction-associated steatotic liver disease (MASLD) on pre-liver transplant mortality	Ami Patel	Received

FRI-194	Risk of all-cause mortality and adverse outcomes from steatotic liver disease and its subgroups in the general population	Maurice Michel	Received

WED-195	NASH-PI: a randomized trial to compare cost-effectiveness across strategies for screening, referring and management of MASLD patients in clinical practice	Manuel Romero-Gómez	Received

SAT-195	Effects of icosabutate, a dual free fatty acid receptor-1 and -4 agonist, on elevated noninvasive markers of liver injury, fibrosis and glycemic control in type 2 diabetic MASH patients and F1-F3 fibrosis	David Fraser	Received

FRI-195	Genetically determined circulating protein biomarkers and risk of advanced fibrosis	Ruby Oberin	Received

THU-195	Synergistic effects of thyroid hormone treatment and mitochondrial thyroid receptor p43 overexpression on regression of metabolic dysfunction-associated steatotic liver disease in mice by improving key mitochondrial quality markers	Raghu Ramanathan	Received

WED-196	Analyses of fibrosis biomarkers PRO-C3 and ELF in resmetirom treated patients from MAESTRO-NASH, a 52 Week NASH/MASH serial liver biopsy study	Quentin M. Anstee	Received

THU-196	Targeting lysyl-tRNA synthetase alleviates metabolic dysfunction-associated steatohepatitis through inhibition of monocyte-derived macrophages in preclinical models	Wonseok Kang	Received

FRI-196	Association between liver histology and long-term clinical outcomes in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease in Sweden: a real-world cohort study (BRIDGE-MASH)	Ying Shang	Received

SAT-196	A significant decrease in steatosis using non-invasive measurements during monitoring for life style changes in patients with MASLD: interim 6m results of a monocentric study	Wouter Robaeys	Received

SAT-197	Higher serum vitamin D levels is associated with lower MASLD prevalence and incidence: the Rotterdam study	Ibrahim Ayada	Received

FRI-197	Implication of recent international consensus criteria for metabolic hyperferritinemia diagnosis and grade in a large cohort of patient with hepatic iron content assessed by magnetic resonance imaging	Edouard Bardou-jacquet	Received

WED-197	How many real world patients diagnosed with metabolic dysfunction-associated steatohepatitis meet clinical trial eligibility criteria? Findings from a large cohort study of more than 18,000 patients from the United States	Claudio Sartini	Received

THU-197	Restoration of natural killer cell antifibrotic activity via a novel immune target; the Neuroligin-4/ß-Neurexin pathway	Johnny Amer	Received

FRI-198	The infamous ballooned hepatocye – fact or fiction: combined data from multiple therapeutic trials including more than 10,000 patients	Julie Dubourg	Received

SAT-198	ASC41, a selective THRß agonist significantly reduces liver fat and ALT in biopsy-confirmed MASH patients after 12-week treatment: an interim analysis of a 52-week serial liver biopsy study	Mingfei Ge	Received

THU-198	In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis	Jieun Song	Received

WED-198	Novel deep learning models utilising domain adaptation outperform conventional statistical models for predicting the risk of liver-related complications in patients with metabolic dysfunction-associated steatotic liver disease	Terry Cheuk-Fung Yip	Received

FRI-199	Insulin resistance as an independent predictor of metabolic dysfunction-associated steatohepatitis (MASH) severity: combined data from multiple therapeutic trials including more than 10,000 patients	Julie Dubourg	Received

WED-199	Optimizing MASLD trial recruitment: LiverPRO vs. FIB-4 in reducing false positives and unnecessary biopsies	Katrine Prier Lindvig	Received

SAT-199	Long term outcomes of Saroglitazar in metabolic-dysfunction associated steatotic liver disease related cirrhosis - a prospective cohort study	Rakhi Maiwall	Received

THU-199	Role and therapeutic potential of miR-22 in MAFLD and obesity: from mouse model to human relevance	Alessandro Toniolo	Received

SAT-200	Statin use is associated with liver fibrosis regression in the general population: a longitudinal analysis of The Rotterdam Study	Jesse Pustjens	Received

WED-200	Prevalence and tissue characteristics of steatotic liver disease subclassifications in the adult UK population using quantitative MRI clinical thresholds: a UK biobank study	Charlie Diamond	Received

FRI-200	Magnitude of steatotic liver disease before and after liver transplantation and the impact of immunosuppressive medication: a multidimensional study	Ibrahim Ayada	Received

THU-200	Clearance of senescent cells alleviates metabolic dysfunction-associated steatohepatitis	Nilofer Sayed	Received

WED-201	Performance of non-invasive tests to diagnose cirrhosis in MASH trials: combined data from multiple therapeutic trials	Julie Dubourg	Received

SAT-201	Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-	Philip N. Newsome	Received

THU-201	Artificial intelligence-assisted multiomics depicting the immunometabolism landscape of steatotic livers undergoing bariatric surgery	Hanyang Liu	Received

FRI-201	Health care resource utilization for patients diagnosed and at high risk of metabolic dysfunction-associated steatohepatitis in Stockholm, Sweden – a REVEAL-MASH study	Helena Skröder	Received

SAT-202	TERN-501, a highly selective thyroid hormone receptor ß agonist, significantly improved MRI-PDFF, cT1, and liver volume in clinically relevant patient populations with presumed MASH: subgroup analyses from a 12-week phase 2a trial	Lois Lee	Received

WED-202	The 2023 AASLD practice guidance for MASLD does not adequately risk stratify MASLD patients in the context of therapeutic trials	Julie Dubourg	Received

THU-202	Prophylactic and therapeutic hepatoprotective effects of the dual FXR/TGR5 agonist INT-767 in the GAN diet-induced ob/ob mouse model of advanced MASH with progressive fibrosis	Jacob Nhr-Meldgaard	Received

FRI-202	Health-Related Quality of Life (HRQL) assessments in a 52-Week, double-blind, randomized, placebo-controlled phase 3 study of Resmetirom (MGL-3196) in patients with nonalcoholic steatohepatitis (NASH) and fibrosis (MAESTRO-NASH)	Carey Escheik	Received

THU-203	Integrated spatial transcriptomics and machine learning derived histopathology measurements in steatotic liver disease unmasks biological heterogeneity of steatosis	Stephen Atkinson	Received

SAT-203	Pegozafermin added to background GLP-1 therapy in patients with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: ENLIVEN 48-week extension data	Cindy Hartsfield	Received

FRI-203	Validation of optimal liver biopsy size for reliable quantitation of fibrosis severity in different areas and structures of liver lobule using second harmonic generation microscopy with artificial intelligence analyses	Nikolai Naoumov	Received

WED-203	Evaluation of iATT liver fat quantification for steatosis grading with reference to magnetic resonance imaging-based proton density fat fraction: a multicenter study	Masashi Hirooka	Received

TOP-204	Inhibition of sodium-glucose cotransporter-2 and liver-related complications in diabetic patients	Sung Won Chung	Received

TOP-205	Effect of a physical exercise program on the cerebral hemodynamics of patients with metabolic dysfunction-associated steatotic liver disease	Berenice M. Román-Calleja	Received

FRI-206	Prevalence and severity of steatotic liver disease in 3,123 at-risk individuals from the background population	Camilla Dalby Hansen	Received

THU-206	Deep learning-based predictive modeling of patatin-like phospholipase domain-containing protein 3 variant carriers using magnetic resonance imaging data	Yazhou Chen	Received

SAT-206	Improvements in MACK-3, a diagnostic test for active metabolic dysfunction-associated steatohepatitis, parallel response to lanifibranor therapy	Michael Cooreman	Received

WED-206	Nash-FibroTest for the diagnosis of significant fibrosis, in severe obesity treated with bariatric surgery and external non-linear trajectories of test´ components among obesity classes in a large US population	Valentina Peta	Received

FRI-207	Sarcopenia in metabolic-dysfunction associated steatotic liver disease (MASLD): unraveling its role in cardiovascular damage	Annalisa Cespiati	Received

THU-207	Brain dysfunction is prevented by alpha 2A adrenergic receptor antagonism in a rodent model of diet-induced metabolic dysfunction-associated steatotic liver disease	Anne Catrine Daugaard Mikkelsen	Received

SAT-207	Safety and efficacy outcomes of endoscopic sleeve gastroplasty and lifestyle intervention in post-orthotopic liver transplant patients: A single-center, prospective pilot study	Jaclyn Tuck	Received

WED-207	Non-invasive biomarkers of liver fibrosis may be used for diagnosing fibrosis and prognostication in patients with metabolic dysfunction-associated steatotic liver disease	Liv Eline Hetland	Received

SAT-208	Sex hormone binding globulin as an effective predictor of treatment response to TERN-501, a potent, highly selective thyroid hormone receptor ß agonist: post-hoc analyses from a 12-week phase 2a trial	Dheepika Weerasinghe	Received

THU-208	Clinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	Jacob Nhr-Meldgaard	Received

WED-208	Metabolomics-based model for predicting metabolic dysfunction-associated steatotic liver disease and stratifying risk	Takeshi KIMURA	Received

FRI-208	qBallooning: AI-based ballooned hepatocyte detection and quantification by second harmonic generation/two photon excitation microscopy	Yayun Ren	Received

SAT-209	A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis	Grazia Pennisi	Received

WED-209	Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD	Eveline Gart	Received

FRI-209	Differential prevalence and prognostic value of metabolic syndrome components among metabolic-dysfunction associated steatotic liver disease (MASLD) patients	Jesse Pustjens	Received

THU-209	Effect of inhibition of the protein tyrosine phosphatase 1B in liver progenitor cells under an steatohepatitis environment in mice	PILAR VALDECANTOS	Received

THU-210	Dysfunctional activation of the DNA damage response is associated with MASLD progression through an E2F2-dependent mechanism	Beatriz Gomez-Santos	Received

SAT-210	Role of Saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in nondiabetic patients: a prospective observational study	JATA SHANKAR KUMAR	Received

WED-210	Plasma metabolite profile associates with liver fibrosis and incident liver-related death in men from finnish general population	Ville Männistö	Received

FRI-210	Increased risk of cancers in metabolic dysfunction-associated steatotic liver disease and MetALD	Yewan Park	Received

WED-211	Combination of Liverfast (LF) & Liver Stiffness Measurement (LSM) using fibroscan uutperforms FIB-4 & LSM, for the identification of MASLD advanced fibrosis (AF) in patients with type 2 diabetes (T2D)	Mona MUNTEANU	Received

THU-211	Hepatoprotective effects of a HSD17b13 inhibitor in the CDAA-HFD mouse model of advanced MASH with?progressive fibrosis	Jacob Nhr-Meldgaard	Received

FRI-211	The presence of autoimmune characteristics in metabolic associated steatosis liver disease patients increases the risk of liver disease progression. Study from the multicentric spanish register (HEPAMET)	Isabel Graupera	Received

SAT-212	Real-world use of Glucagon-like peptide 1 receptor agonists in patients with MASLD: a cross-sectional analysis from TARGET-NASH	A. Sidney Barritt IV	Received

WED-212	Pemvidutide treatment is associated with improvement in noninvasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-control	Jonathan Kasper	Received

SAT-213	Postbiotic supplementation for metabolic dysfunction-associated steatotic liver disease	Nazarii Kobyliak	Received

THU-213	Exploring the role of FXR activation in mitigating ceramides-driven lipotoxicity and endoplasmic reticulum stress in metabolic dysfunction associated steatohepatitis	Basma Alaa	Received

FRI-213	Low-to-moderate alcohol consumption is associated with increased fibrosis in subjects with metabolic dysfunction-associated steatotic liver disease	Maria Teresa Arias Loste	Received

WED-213	Assessment of fibrosis change rates in placebo arm of metabolic dysfunction-associated steatohepatitis drug trials based on pathologist readouts and qFibrosis continuous values	Kutbuddin Akbary	Received

THU-214	Spatiotemporal non-invasive characterization of the hepatic microenvironment during metabolic dysfunction-associated liver disease progression	Rallia-Iliana Velliou	Received

WED-214	Ferritin is a predictor of fibrosis, but not liver iron in metabolic hyperferritinaemia	Maria Rosina Troppmair	Received

SAT-214	Using machine learning models to predict baseline fibrosis stage in patients from phase 3 resmetirom trials (MAESTRO-NAFLD and MAESTRO-NASH)	Jörn M Schattenberg	Received

FRI-214	Risk of non-alcoholic steatohepatitis disease progression to more severe liver disease in medicare patients	Dominic Nunag	Received

THU-215	Artificial intelligence-derived granular histological markers of fibrosis from hematoxylin and eosin-stained whole slide images associate with non-invasive tests of fibrosis and prognosis to cirrhosis in patients with metabolic dysfunction-associated stea	Lara Murray	Received

WED-215	HeparDx™ (by Metadeq, Inc.) is a reliable biomarker-based non-invasive test for MASH, capable of detecting the presence of inflammation and ballooning	Giulia Angelini	Received

SAT-215	Healthcare cost and resource utilization among patients with non-alcoholic steatohepatitis (NASH), stratified by glucagon-like peptide 1 receptor agonist (GLP-1) use in real world data	Taylor Marlin	Received

FRI-215	MASL-B registry: results from a european cohort of patients with chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease	Roberta Forlano	Received

TOP-216	The three strain probiotics for metabolic dysfunction-associated steatotic liver disease improvement: a parallel, double-blind, randomized, placebo-controlled trial	Sung-Min Won	Received

TOP-217	A randomized, placebo-controlled phase Ib/IIa trial to evaluate the safety, tolerability, and efficacy of BGT-002, an adenosine triphosphate citrate lyase inhibitor in patients with NAFLD: interim analysis	Yue Hu	Received

THU-218	A novel role for the epigenetic regulator SUV420H1 in MASLD and its complications	Alessia Pagani	Received

FRI-218	Cost of inaction for metabolic dysfunction-associated steatohepatitis (MASH): the projected economic burden in the United States	Carey Escheik	Received

WED-218	Circulating mitochondrial bioenergetic profile reflects the hepatic one and represents a non-invasive biomarker of disease severity in MASLD genetically predisposed individuals	erika paolini	Received

SAT-218	Liver fibrosis and obesity associated with stroke in an elderly population: protected effect by pravastatin	Willy Theel	Received

SAT-219	Discovering 1-piperidine propionic acid inhibiting effect on protease activated receptor 2 and serpinb3 as a new therapeutic strategy for metabolic dysfunction-associated steatohepatitis	Monica Chinellato	Received

FRI-219	Recompensation and liver function improvement in patients with decompensated cirrhosis due to metabolic-dysfunction associated steatotic liver disease (MASLD): a retrospective cohort study	Alba Jiménez-Masip	Received

WED-219	Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model	Jonathan Kasper	Received

THU-219	Inhibition of HSD17B13 by INI-822 phenocopies the hepatic lipidomic profile of humans with the protective allele	Heather Hsu	Received

SAT-220	Efruxifermin treatment improved collagen biomarkers consistent with remodelling of the extracellular matrix in patients with F2-F3 fibrosis due to MASH	Erik Tillman	Received

THU-220	ATM, guardian of genome integrity, is a new player in NAFLD pathogenesis by modulating mitochondrial metabolism	DESDOUETS CHANTAL	Received

FRI-220	The unrecognised burden of pruritus in metabolic dysfunction associated steatotic liver disease	Amber Garrick	Received

WED-220	BOS-580, a long-acting FGF-21 analogue, treatment shows beneficial changes in the circulating lipidome and improves MASEF score in patients with phenotypic metabolic dysfunction-associated steatohepatitis in a phase 2a randomized, placebo-controlled, 12-w	Cindy Xu	Received

FRI-221	Prevalence and mortality of the spectrum of steatotic liver disease (SLD) in the US populations	Carey Escheik	Received

SAT-221	Effectiveness of Polyene phosphatidylcholine in metabolic-associated fatty liver disease treatment : a real-world study in China	Nandini Pandey	Received

THU-221	Association of non-invasive tests (NITs) with genetic polymorphism in patients with metabolic dysfunction–associated steatotic liver disease (MASLD)	Carey Escheik	Received

WED-221	A novel point-of-care prediction model for steatotic liver disease: based on bioimpedance analysis	Jeayeon Park	Received

FRI-222	A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease	Ian P. OConnor	Received

WED-222	IMPACT OF AUTOMATED FIB-4 REPORTING ON LIVER-RELATED REFERRAL OF PATIENTS WITH DIABETES	Theodore Feldman	Received

THU-222	The exercise-induced metabokine beta-aminoisobutyric acid regulates hepatic lipid metabolism and reduces hepatic metabolic dysfunction and fatty liver in a dietary obese mouse model	Shaimaa Gad	Received

THU-223	A novel circular RNA therapy expressing a long-acting FGF21 analog protein reversed obesity, insulin resistance, and steatosis in mouse models	Rui Cao	Received

WED-223	Clinical and biological predictors of liver fat content = 8% as assessed by MRI-PDFF: combined data from multiple therapeutic trials including more than 10,000 patients	Julie Dubourg	Received

THU-224	CRISPR/Cas9-mediated somatic gene editing in adult mice reveals hepatic KLB as a regulator of bile acid synthesis and hepatic lipid metabolism	Alexandra Aaldijk	Received

WED-224	Screening for liver fibrosis in tertiary care using automatic calculation of FIB4 in patients at-risk of diabetes	Clémence M Canivet	Received

FRI-224	Intramyocellular lipids are associated with insulin resistance in metabolic dysfunction-associated steatotic liver disease	Guillaume Henin	Received

SAT-224	Pharmacokinetics of the selective glucocorticoid receptor modulator miricorilant in healthy volunteers and patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)	Valerie Hilliard	Received

WED-225	An intergenerational population-based cross-sectional study of MASLD in children and their parents	Oyekoya Ayonrinde	Received

THU-225	GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis by attenuating SMAD3 phosphorylation	Javier Jurado-Aguilar	Received

SAT-225	Berberine Ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance	Kjersti Swearingen	Received

THU-226	CAMSAP1 aggravates liver fibrosis in metabolic dysfunction-associated steatohepatitis by promoting microtubule acetylation	Zhiping Wan	Received

FRI-226	The impact of light to moderate alcohol consumption on liver and cardiovascular damage in metabolic-dysfunction associated steatotic liver disease	Rosa Lombardi	Received

SAT-226	Statin prescriptions and progression to a high-risk for advanced fibrosis in primary care patients with metabolic dysfunction-associated steatotic liver disease (MASLD)	Andrew Schreiner	Received

WED-226	An algorithm based on serum phospholipid profiles to predict liver fibrosis degree in metabolic dysfunction–associated steatotic liver disease	Mayuko Shimizu	Received

THU-227	Macrophage phenotype is affected by longitudinal treatment with Zalfermin in a model of metabolic dysfunction-associated steatohepatitis	Benedicte Kapel	Received

SAT-227	Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM	Kjersti Swearingen	Received

WED-227	Transient elastography performance for the diagnosis of liver fibrosis in MASLD is independent of steatosis level as determined by MRI proton density fat fraction in a prospective multicentrer study	edouard bardou-jacquet	Received

FRI-227	Impact of antidiabetic medications on adverse liver outcomes in patients with type 2 diabetes mellitus: independent and interactive effects	Sherlot Song	Received

TOP-228	CD36-mediated hepatocyte-macrophage coordination drives hepatic fibrosis in MASLD	Zhe Dai	Received

TOP-229	The E2F2 target glycerophosphodiester phosphodiesterase domain containing 3 is involved in MASLD progression to HCC and related dyslipidemias	Maider Apodaka Biguri	Received

FRI-230	Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated hepatological and non-hepatological healthcare pathway model: preliminary results from a prospective cohort of a tertiary center	Angelo Armandi	Received

THU-230	Human embryonic stem cell-derived mesenchymal stem cells improve mitochondrial oxidative dysfunction in metabolic dysfunction-associated liver disease via the AMPK pathway	Yun Bin Lee	Received

WED-230	Association of Quantitative Hepatic Collagen with Non-Invasive Tests (NITs) for Fibrosis in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)	Carey Escheik	Received

FRI-231	Compared to complete abstainers, non-significant alcohol use may be associated with more severe liver disease in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – The multicentre study of the indian consortium on MASLD	AJAY KUMAR DUSEJA	Received

THU-231	Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of NASH and cardiovascular health in LDL receptor knockout NASH mice	Wen-Wei Tsai	Received

SAT-231	GL0034 (Utreglutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study	Rajamannar Thennati	Received

WED-231	Machine learning-based mortality prediction models for non-alcoholic fatty liver disease in the general United States population	Jiarui Zheng	Received

THU-232	Additive hepatoprotective effects of DA-1241, a novel GPR119 agonist, in combination with semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	Jacob Nhr-Meldgaard	Received

WED-232	Diagnostic accuracy of two-dimensional shear wave elastography (2D-SWE) for non-invasive assessment of liver fibrosis in biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD). Systematic-review and multi-level random effects model	Madalina-Gabriela Taru	Received

FRI-232	In Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Clinically Significant Pruritus is Associated with High Serum Bile Acid (BA) Level and Advanced Fibrosis (AF)	Carey Escheik	Received

FRI-233	Cardiovascular disease burden in patients with and without metabolic dysfunction-associated steatohepatitis: data from the unCoVer-MASH longitudinal cohort study	Elisabetta Bugianesi	Received

THU-233	External validation of machine learning model (MASML) adjusted for prevalence for determining the histologic severity of MASLD in a large cohort of patients with biopsy-proven disease	Joseph Rubinsztain	Received

WED-233	The single nucleotide polymorphism rs780094 C>T in the glucokinase regulator gene (GCKR) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic dysfunction-associated steatotic liver disea	Eleonora Dileo	Received

SAT-233	Clinical pharmacokinetics of INI-822, a small molecule inhibitor of HSD17B13	Heather Hsu	Received

WED-234	Identifying the optimal cut off for relative reduction in liver fat content on MRI-PDFF to predict histologic response in MASH clinical trials	Cayden Beyer	Received

THU-234	Development of a new mouse model combining rapid and robust MASH, liver fibrosis and atherosclerosis: time- and sex-dependent effects	Fanny Lalloyer	Received

FRI-234	Association between the duration of comorbidities and steatotic liver disease	HA IL KIM	Received

FRI-235	Causes of death, mortality rates, and the role of socio-demographic risk factors and biomarkers in metabolic dysfunction-associated steatohepatitis mortality in more than 18,000 real world patients from the United States	Claudio Sartini	Received

WED-235	Prediction of metabolic dysfunction-associated steatohepatitis resolution	Rohit Loomba	Received

THU-235	Bridging hepatic pathologies: protein expression dynamics in metabolic dysfunction-associated liver disease (MASLD), benign liver tumours and hepatocellular carcinoma	Saima ajaz	Received

WED-236	Real world evaluation of a primary care pathway for the assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)	Basil Ahmad	Received

SAT-236	Efficacy and safety of incretin-based therapies in patients with metabolic dysfunction-associated steatotic liver disease complicated by type 2 diabetes mellitus	Tadamichi Kawano	Received

THU-236	Oxysterol treatment causes indirect stellate cell activation: a potential mechanism linking steroid metabolising enzyme dysregulation with fibrosis	Hamish Miller	Received

FRI-236	Racial disparities in incidence of cirrhosis and extrahepatic manifestations in metabolic dysfunction-associated steatotic liver disease	Majd Aboona	Received

SAT-237	Efficacy and safety of FGF21 analogues in the treatment of metabolic dysfunction-associated steatohepatitis: an updated systematic review and meta-analysis	Gilmara Coelho Meine	Received

FRI-237	Natural history of lean and non-lean metabolic dysfunction associated steatotic liver disease	Shun-ichi Wakabayashi	Received

FRI-238	Histological and clinical disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy	Merve Ekelik	Received

SAT-238	Statins are not associated with an increased risk of decompensated cirrhosis in patients with type 2 diabetes mellitus	Jonathan Tjerkaski	Received

WED-238	High pancreatic fat and reduced volume stratify patients with F4 liver fibrosis	Edward Jackson	Received

SAT-239	A phase 4, multicenter, open-label, single-arm study to evaluate the safety and efficacy of saroglitazar 4 mg in patients with non-alcoholic fatty liver disease with obesity, type 2 diabetes mellitus, dyslipidemia, or metabolic syndrome	Deven Parmar	Received

THU-239	Metabolic dysfunction-associated steatotic liver disease (MASLD) modeling with hepatocyte-like cells derived from adult liver stem cells via air-liquid interface	Soe Einsi Lynn	Received

WED-239	Proteomics identifies a subpopulation of plasma extracellular vesicles able to improve non-invasive diagnosis of MASH in patients with type 2 diabetes: results of the RHU QUID-NASH study	LAURE ELKRIEF	Received

FRI-239	An inference model of risk factors for liver-related complications among patients with type 2 diabetes mellitus	Sherlot Song	Received

TOP-240	Hepatic mitochondrial reductive stress predicts liver mortality in the UK biobank	Juho Asteljoki	Received

TOP-241	Longitudinal changes in liver stiffness measurements in a population-based screening cohort of 5,517 participants	Katrine Bech	Received

THU-242	Comparison of machine learning model (MASML), VCTE, and FIB-4 scores for predicting the presence of MASLD in a large cohort of patients in the U.S. using the NHANES database	Joseph Rubinsztain	Received

WED-242	The use of ELF test, FIB-4 and sequential algorithms to screen the Type 2 Diabetes Mellitus (T2DM) population for advanced fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Yiying Pei	Received

FRI-242	Redefining the relationship: the diminished correlation between MASLD and CKD after accounting for diabetes or insulin resistance	Tianyuan Yang	Received

SAT-242	Efficacy and safety of FGF-analogs for the treatment of MASH: a systematic review and meta-analysis	Maria Viana	Received

THU-243	Macrophage driven fibrosis resolution assessed by a cross-linked and MMP degraded type III collagen fragment (CTX-III) declines with age and is prognostic for survival in chronic liver disease	Alejandro E Mayorca-Guiliani	Received

FRI-243	Echocardiography-based markers of subclinical cardiac dysfunction in patients with MASLD and preserved ejection fraction: prospective data from the Turin cohort	Kamela Gjini	Received

SAT-243	Time course of onset, incidence and prevalence of gastrointestinal adverse events with HTD1801 (Berberine Ursodeoxycholate) in patients with MASH and T2DM	Kjersti Swearingen	Received

WED-243	Irisin level as a potential biomarker for hepatic steatosis improvement after a 6-month lifestyle intervention in patients with metabolic dysfunction-associated steatotic liver disease	Gabriele Castelnuovo	Received

FRI-244	Barriers and motivators for implementation of lifestyle changes in a large population with MASLD	Sharon Oude Veldhuis	Received

THU-244	Synergistic hepatoprotective effects of semaglutide and resmetirom combination therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	Kristoffer Voldum-Clausen	Received

SAT-244	FGF-19 analogues for the treatment of metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis	Gilmara Coelho Meine	Received

WED-244	The diminished diagnostic accuracy of existing non-invasive tools for significant fibrosis in MASLD patients concurrent with CHB	Yee Yeo	Received

WED-245	Should specific cutoffs be used for diagnosing fibrotic MASH in patients with type 2 diabetes using FAST, MAST, MEFIB and FNI?	Laurent Castera	Received

THU-245	Assessing the diagnostic accuracy of ChatGPT-4 in the histopathological evaluation of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)	Luca Di Tommaso	Received

FRI-245	Longitudinal follow-up of Fib-4 in patients at risk of steatotic liver disease (SLD) receiving low-dose Methotrexate treatment (LD-MTX): results from the CIRT randomized placebo-controlled Trial in 4769 patients	Vincent Di Martino	Received

SAT-245	Semaglutide for type 2 diabetes control in metabolic dysfunction-associated steatotic liver disease (MASLD): a two-way effect?	Giovanni Petralli	Received

FRI-247	Association of plasma magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10,000 patients	Julie Dubourg	Received

THU-247	Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide: diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity	Charlotte Hateley	Received

WED-247	Unravelling metabolic dysfunction-associated steatotic liver disease with a Bayesian network approach in the UK biobank	Benjamin P.M. Laevens	Received

SAT-248	Liver stiffness improvement with pioglitazone in brazilian patients with metabolic dysfunction-associated steatohepatitis: a multicentric pilot study	Mário Pessoa	Received

THU-248	Unraveling the interplay of FGF21 and GLP1 analogue in metabolic dysfunction-associated steatohepatitis in vivo	Anouk Oldenburger	Received

WED-248	A four-country modelling study on doubling MASH diagnostic rates by 2027	Jeffrey Lazarus	Received

FRI-248	The impact of baseline sarcopenia, over time, on liver and cardiovascular damage in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a prospective study	FLORIANA SANTOMENNA	Received

FRI-249	Association between uric acid concentration and MASH: combined data from multiple therapeutic trials including more than 10,000 patients	Julie Dubourg	Received

THU-249	The role of the ferroptosis brake glutathione peroxidase 4 in a preclinical model of metabolic dysfunction-associated steatohepatitis	Wilhelmus Kwanten	Received

WED-249	Improved risk stratification by combination of FIB-4 with FGF21 serum levels in steatotic liver disease	Heike Bantel	Received

WED-250	PNPLA3 I148M a useful diagnostic marker for significant fibrosis metabolic dysfunction-associated steatotic liver disease	Elias Rashu	Received

THU-250	Untargeted lipidomics unveils distinct signature of metabolic dysfunction-associated steatohepatitis in the context of obesity	Alina-Iuliana Onoiu	Received

FRI-250	An intergenerational study of the prevalence and cardiometabolic significance of steatotic liver disease in adults in the Raine Study	Oyekoya Ayonrinde	Received

SAT-250	Substituting FIB-4 with LiverPRO as an initial test for detecting advanced fibrosis leads to a 6-fold reduction in false positive results	Katrine Lindvig	Received

WED-251	Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steato	Jonathan Kasper	Received

SAT-251	Semaglutide can reduce alcohol use in patients with metabolic dysfunction-associated steatotic liver disease	Sonal Kumar	Received

FRI-251	Hepatic steatosis contributes to cognitive impairment in patients with metabolic dysfunction-associated steatotic liver disease and/or type 2 diabetes-mellitus	Nuria Pérez Diaz del Campo	Received

THU-251	Liver sinusoidal endothelial cells induce senescence in activated hepatic stellate cells via extracellular vesicles	Junyu Wang	Received

TOP-252	Longitudinal changes of FIB-4 do not predict outcomes in patients with metabolic dysfunction-associated steatotic liver disease	Hannes Hegmar	Received

TOP-253	Clinical, biological and imaging predictors of at-risk MASH: combined data from multiple therapeutic trials including more than 10,000 patients	Julie Dubourg	Received

WED-254	The true diagnostic performance of magnetic resonance elastography for the detection of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease exceeds the diagnostic performance of liver biopsy	Ian Rowe	Received

THU-254	Differential gene expression profiles of liver tissue, subcutaneous and visceral adipose tissue delineates severity of MASLD in heavily obese patients	Lina Jegodzinski	Received

SAT-254	Diet modifies the association between alcohol intake and alcohol-related liver disease: a prospective study of individual patient data from the UK Biobank	Ewan H Forrest	Received

FRI-254	Global prevalence, clinical characteristics, histology and outcomes of PNPLA3 I148M variant in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis	Matheus Souza	Received

SAT-255	Assessing LSM thresholds to identify clinically relevant SLD in individuals with excessive alcohol intake and absence of steatosis	Mette Andersen	Received

THU-255	Calcitriol modulates intestinal AMPK/SIRT1 signaling towards alleviating compromised barrier integrity in MASH: a potential autophagy-dependent role	Andrew Hakeem	Received

WED-255	Muscle composition as a predictor of advanced fibrosis in chronic liver disease	Wile Balkhed	Received

FRI-255	Modeling the burden of steatotic liver disease and its subcategories in people living with HIV in Germany	Maurice Michel	Received

FRI-256	Patients with metabolic-associated steatotic liver disease and portal hypertension have different skeletal muscle and adipose tissue mass than patients with other causes of cirrhosis	Ikram Abow-Mohamed	Received

THU-256	Without effect on weight loss, semaglutide does not improve MASLD in a dietary mice model for MASLD	Katharina Luise Hupa-Breier	Received

WED-256	The influence of rifaximin on bile acids composition	Olena Barabanchyk	Received

SAT-257	Hepatorenal syndrome markedly impacts prognosis of patients with alcohol-associated hepatitis. Results from the spanish registry of alcohol-associated liver disease (REHALC)	Jordi Gratacós-Ginès	Received

THU-257	Metabolic profiling of adipose tissues in metabolic dysfunction-associated steatohepatitis (MASH): insights from lipidomic, proteomic, and epigenetic analyses in morbidly obese patients undergoing bariatric surgery	Cristina Placed-Gallego	Received

FRI-257	Metabolic dysfunction associated steatohepatitis (MASH) disease progression phenotyping features based on medical claims	Magda Berberova	Received

WED-257	FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis	Laura Martínez-Arenas	Received

THU-258	Altered liver vascular biology occurring in early stages of metabolic dysfunction-associated steatotic liver disease is significantly improved by the pan-peroxisome proliferator-activated receptor agonist lanifibranor, associating with improved liver hist	Shivani Chotkoe	Received

FRI-258	Pruritus is frequent, burdensome, and persistent in metabolic dysfunction-associated steatohepatitis (MASH) and primary biliary cholangitis (PBC): a 6-month longitudinal study	Anna Halliday	Received

WED-259	Metabolic dysfunction-associated steatotic liver disease prevalence and predictors in patients with type 2 diabetes in primary care	Wile Balkhed	Received

THU-259	Non-invasive staging of liver disease in C57BL/6NTac mice preconditioned on the modified-Amylin NASH diet using automated shear wave elastography	Caroline Mitchell	Received

FRI-259	A real-life multidisciplinary clinic approach for the management of metabolic dysfunction associated steatotic liver disease	Raluca Pais	Received

FRI-260	Diagnosed prevalence of cardio-renal diseases, mental health disorders, sleep apnea, cancer, and mortality rates in more than 18,000 patients with metabolic dysfunction-associated steatohepatitis with and without cirrhosis from the United States	Claudio Sartini	Received

WED-260	Comparative analysis of Agile 3+, NFS, and BARD scores for diagnosing advanced fibrosis in MASLD and MetALD	Sae Kyung Joo	Received

THU-260	Serum thrombospondin-2 and insulin -like growth factor binding protein 7 predict liver fibrosis and fibrosis regression in patients with MASLD post bariatric surgery	RAMBABU SURABATTULA	Received

SAT-260	Metadoxine improves alcohol abstinence and is related to a lower risk of decompensation in cirrhosis at a median five-year follow-up: propensity score matching analysis	Fatima Higuera	Received

FRI-261	Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up	Hun Jee Choe	Received

SAT-261	Preliminary results of a phase I study of SZN-043, a novel R-Spondin mimetic, in healthy volunteers and subjects with liver cirrhosis	Jay Tibbitts	Received

WED-261	Prognostic significance of ELF test compared to liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)	Antonio Liguori	Received

THU-261	Artificial intelligence models deployed at scale on hematoxylin and eosin-stained whole slide images reveal stage-dependent collagen composition in metabolic dysfunction-associated steatohepatitis	Lara Murray	Received

FRI-262	Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease is Independently Associated with Reduced Kidney Function	Gres Karim	Received

SAT-262	Assessing efficacy and safety of baclofen in the management of alcohol dependence among patients with alcoholic liver disease	Berta López-Sáez	Received

THU-262	Targeting macrophage BTK, a potential therapeutic strategy for metabolic dysfunction-associated steatohepatitis	Shiwei Chen	Received

THU-263	Significance of adipose tissue fibrosis and adipocyte in the progression of metabolic dysfunction-associated steatohepatitis in severe obesity patients	Andrea Jiménez-Franco	Received

SAT-263	Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy study	Vlad Ratziu	Received

FRI-263	Severity of hepatic steatosis measured with controlled attenuation parameter as a determinant of carotid atherosclerosis in the Raine Study	Oyekoya Ayonrinde	Received

WED-263	A machine learning approach to identify patient features associated with metabolic dysfunction-associated steatohepatitis from the United Kingdom biobank	Elayna Livingstone	Received

TOP-264	Paired assessment of enhanced liver fibrosis (ELF) and fibrosis-4 (FIB-4) scores is associated with an elevated risk of liver-related clinical events in participants with advanced fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH)	Ruby Oberin	Received

TOP-265	Non-invasive predictive markers of resmetirom biopsy response	Jörn M Schattenberg	Received

THU-266	S100A11 is a pro-inflammatory lipotoxic damage associated molecular pattern in metabolic dysfunction-associated steatohepatitis	Gopanandan Parthasarathy	Received

FRI-266	Temporal trends in the profile of non-alcoholic fatty liver disease: a decadal experience	Prajna Anirvan	Received

SAT-266	Fibrosis stage progression in alcohol-related liver disease evaluated by repeated biopsies	Ellen Lyngbeck Jensen	Received

WED-266	Age impacts the diagnostic ability of the enhanced liver fibrosis test for advanced fibrosis in MASLD	Katrina Pekarska	Received

SAT-267	The interaction between metabolic syndrome and alcohol consumption after an episode of alcohol-associated hepatitis is associated with increased mortality: results from de spanish registry of alcohol-associated liver disease (REHALC)	Jordi Gratacós-Ginès	Received

FRI-267	Regional fibrosis progression analysed by digital pathology with artificial intelligence is associated with renal dysfunction	Ya-Yun Ren	Received

WED-267	The FAP Index: A statistical model aiding the detection of advanced liver fibrosis in people with diabetes, obesity or metabolic dysfunction-associated steatosis using a marker of activated stellate cells and myofibroblasts	Mark Gorrell	Received

FRI-268	MASH not NASH: A contemporary study of the impact of cardiac arrythmias	Charles Yang	Received

WED-268	Natural history and expected change over time for MRI derived cT1: Data from clinical trials and the UK Biobank	Charlie Diamond	Received

SAT-268	Bariatric surgery is a major independent factor of disease progression in cirrhotic patients with alcohol-related liver disease	Louis Onghena	Received

THU-268	Differential transcriptomic profile in platelet-derived extracellular vesicles in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Sheila Gato-Zambrano	Received

THU-269	Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunctions-associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthase-inhibition	Niklas Geiger	Received

WED-269	Simultaneous assessment of skeletal muscle mass and handgrip strength to identify patients with NAFLD at high risk of advanced liver fibrosis	Seung Up Kim	Received

SAT-269	Portal hypertension in alcohol-related hepatitis: natural history and prognostic value	Karim Gebara	Received

WED-270	Clinical profile of patients considered at-risk for MASH with fibrosis identified through an ongoing global screening program with genetics	Samuel Daniels	Received

FRI-271	Hepatitis C infection increases the risk of new-onset HTN and DM among patients with metabolic dysfunction-associated steatotic liver disease	Ping-Tsung Shih	Received

THU-271	Brain inflammation and cognitive impairment is not mitigated by a low-fat dietary intervention in ageing mice with MASLD	Matthew Siddle	Received

WED-271	Circulating vesicle microRNAs for metabolic dysfunction-associated steatotic liver disease (MASLD) staging and progression towards liver cancer	Laura Izquierdo Sanchez	Received

SAT-272	Updated definition of healthy alanine aminotransferase levels in a metabolically and histologically normal population	Jonggi Choi	Received

FRI-272	Steatotic liver disease with normal liver enzyme: clinical use of ultrasound attenuation method and share wave elastography	Shunsuke Sato	Received

THU-272	MASH-associated endothelial dysfunction in mice: is there no effect?	Justine Lallement	Received

THU-273	Distinct gut microbiome and intestinal permeability biomarker in patients with lean MASLD without type 2 diabetes	NATTHAYA CHUAYPEN	Received

SAT-273	Is it worth staining for hepatic glucocorticoid receptors in alcohol related hepatitis?	Mina Ignat	Received

FRI-273	Prevalence, characteristics and hepatic fibrosis burden of the different subtypes of steatotic liver disease among a cohort of Egyptian people living with HIV	Ahmed Cordie	Received

WED-273	The performance of the enhanced liver fibrosis test by cardiometabolic risk factors in patients with metabolic dysfunction-associated steatotic liver disease	Kazuhito Kawata	Received

WED-274	Impact of sex, body mass index, elevated liver enzymes, and diabetes mellitus on risk-stratification of a large cohort of patients with MASLD	Abdel-Aziz Shaheen	Received

FRI-274	Persistence of fatty liver index (FLI) = 20 as a predictor for hepatocellular carcinoma (HCC) development in non-HBV/non-HCV infected population	Rachel Wen-Juei Jeng	Received

SAT-274	Serum proteomic analyses reveal elevated HGF and IL-8 in patients with alcohol-related hepatitis compared to decompensated alcohol-related cirrhosis and can differentiate patients with AH at risk of infection from those at risk of acute kidney injury	Luke Tyson	Received

THU-274	Targeting mitochondrial complex I modulates lipid metabolism, inflammation and hepatic fibrosis in a MCD-diet model of benign steatosis	Francesca Protopapa	Received

WED-275	Understanding barriers to adoption of clinical guidelines for metabolic dysfunction-associated steatotic liver disease among hepatologists in Europe	Laurent Castera	Received

THU-275	Interleukin 10 reduces fat accumulation and promotes fatty acid degradation and intracellular glucose maintenance in a high-fat-diet mouse model of metabolic dysfunction-associated steatotic liver disease	Akira Kado	Received

FRI-275	Liver fibrosis and Lipoprotein(a) levels in individuals with metabolic dysfunction	Sara Margarita	Received

SAT-275	Role of neutrophil lymphocyte ratio in transition of alcoholic cirrhosis with acute decompensation to unstable decompensated cirrhosis	Feixiang Xiong	Received

TOP-276	Time-trends of fibrosis and steatosis in metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective cohort analysis	Umang Arora	Received

TOP-277	Liver fibrosis assessed via non-invasive tests is associated with incident heart failure in a general population cohort: a UK Biobank study	Theresa Hydes	Received

THU-278	Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model	Radina Kostadinova	Received

WED-278	MASLD assessment using a novel point of care device the Hepatoscope™ in diabetes and obesity clinics	Joel Gay	Received

SAT-278	FIB-4 score as a predictor of mortality outcomes in individuals with metabolic dysfunction-associated steatotic liver disease with moderate alcohol consumption: a nationwide cohort study	Majd Aboona	Received

FRI-278	The risk of cardiometabolic disease related to increasing amounts of liver fat above the cut-off of 5%	Gabrielle Alblas	Received

FRI-279	Platelet dynamics in metabolic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and liver cirrhosis	Mirko Zoncapè	Received

SAT-279	Transplantation for alcoholic liver disease: impact of on-site substance use disorder treatment on outcome	Shehzad Niazi	Received

THU-279	Time-restricted feeding alleviates metabolic associated fatty liver disease via PPAR-related lipid metabolism signaling pathway	Juanjuan Shi	Received

WED-279	Landscape of the steatotic liver disease and its risk factors in the point-of-care liver screening program SIRIUS	Tomas Koller	Received

WED-280	Spectroscopy of blood plasma has the potential to differentiate metabolic dysfunction-associated steatohepatitis from steatosis	Barbora Nováková	Received

SAT-280	Emergence of co-morbidities in alcohol-related hepatitis over time: insights from the WALDO cohort	Douglas Corrigall	Received

FRI-280	Dynamic of cardiometabolic components are highly correlated with the risk of hypertension and diabetes among patients with metabolic dysfunction-associated steatotic liver disease	Chin-I Shih	Received

WED-281	A non-invasive score model for prediction of significant fibrosis and fibrotic metabolic dysfunction-associated steatohepatitis based on serum biomolecules	Nateneal Beyene	Received

THU-281	Gut dysbiosis is associated with the severity of liver fibrosis assessed by magnetic resonance elastography in patients with MAFLD	THANANYA JINATO	Received

SAT-281	Clinical characteristics, surveillance, treatment allocation and outcomes of alcohol-related hepatocellular carcinoma: meta-analysis of 37 studies and 66,559 patients	Daniel Tung	Received

FRI-282	Obese patients with sarcopenic obesity have a more severe metabolic phenotype and hepatic disease and exhibit less metabolic improvement after bariatric surgery	Vittoria Zambon	Received

WED-283	The distribution of fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction associated steatotic liver disease in the general population.	Yuji Ogawa	Received

THU-283	Characterisation of peptidylprolyl isomerase C as a novel player in the pathogenesis of chronic liver disease	Ana Blas-García	Received

FRI-283	Costs associated with non-alcoholic steatohepatitis disease progression in medicare patients	Dominic Nunag	Received

FRI-284	A plant-based diet for liver health: the protective role of vegetable fat on MASLD and other liver diesases	Simon Schophaus	Received

WED-284	The Fatty Liver Index (FLI) is more accurate than FIB-4 for detection of advanced liver fibrosis in patients with type-2 Diabetes Mellitus (T2DM) in Primary Care.	Ruth Nadal	Received

THU-284	Prediction of MASH features from liver biopsy images using a pre-trained self-supervised learning model	Saurabh Vyawahare	Received

WED-285	Predicting significant hepatic steatosis from routine biochemistry in people with and without type 2 diabetes (T2D)	Magdalena Nowak	Received

SAT-285	Incorporation of cholestasis into prognostic models improves predictive outcome in alcohol-related liver disease: a retrospective multicenter study	Mohsen Subhani	Received

THU-285	Low nonpsychedelic dosed of psilocybin for the therapy of MASLD	Martina Colognesi	Received

SAT-286	Long-term risk of alcohol-related liver disease after community-based treatment for alcohol use disorder: a nationwide register based cohort study from Denmark	Line Molzen	Received

WED-286	Identification of serum metabolome signatures associated with hepatocellular carcinoma in metabolic dysfunction-associated steatohepatitis	Atsumasa Komori	Received

FRI-286	Muscle function and walking time are associated with better quality of life in MASLD patients	Roberta Forlano	Received

THU-286	PNPLA3 p.I148M variant affects lipid droplets number and size in patient-derived liver organoids	Elia Casirati	Received

WED-287	Sequential approach using combination of newly developed HOMA2-IR-ALT-TE-MASH (HALT-M) score and magnetic resonance elastography for non-invasive identifying at-risk metabolic dysfunction-associated steatohepatitis in obese subjects	Seung Kak Shin	Received

THU-287	Dysregulation of ureagenesis and glutaminolysis in DIAMONDTM mice played a major role in MASLD progression	Rocío Gallego-Durán	Received

SAT-287	Association between serum homocysteine levels and advanced hepatic fibrosis in alcohol-related liver disease: a cross-sectional study	Hui Yang	Received

TOP-288	Serum GDF15 level, in combination with the FIB-4 index, is useful for refining the identification of high-risk patients for clinical event occurrence in MASLD patients	Hayato Hikita	Received

TOP-289	Artificial intelligence-based measurement of nonalcoholic steatohepatitis is an accurate tool for clinical trial enrollment and endpoint assessment	Lara Murray	Received

FRI-290	Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness	Nicola Pugliese	Received

WED-290	Assessment of transient elastography (FibroScan) in obesity patients with nonalcoholic fatty liver disease: a meta-analysis	Ziping Lin	Received

THU-290	Single nucleotide polymorphism analysis for predicting metabolic-associated fatty liver disease development in patients with severe obesity (types II and III)	Juan Manuel Jiménez-Aguilar	Received

SAT-290	Natural history of varices in patients with severe alcohol-associated hepatitis	SHARATH S	Received

SAT-291	Screening for alcohol related liver disease in acute hospital admissions	Jessica Lovatt	Received

FRI-291	Stigma in steatotic liver disease (SLD): a survey of patients from Saudi Arabia	Khalid A Alswat	Received

WED-291	New optimal cut-points for vibration controlled transient elastography and MR elastography for advanced fibrosis in hispanic versus non-hispanic adults with metabolic dysfunction-associated steatotic liver disease	Monica Tincopa	Received

THU-291	Cellular senescence is a common hallmark in diverse models of steatotic liver diseases	Charalampos Pavlidis	Received

WED-292	Noninvasive diagnosis of significant portal hypertension based on prealbumin proteomics model	xiaoyan wang	Received

SAT-292	Coinfection with viral hepatitis increases the short-term but not the long-term risks of hepatocellular carcinoma and hepatic events in adults with alcohol-related cirrhosis	vicki wing-ki hui	Received

WED-293	Effectiveness of on different models of care based on Fibrosis-4 and/or liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease	Gian Paolo Caviglia	Received

THU-293	Non-invasive assessment of liver inflammation in metabolic dysfunction-associated steatohepatitis (MASH) using MRI cytometry	Xiaoyu Jiang	Received

FRI-293	Association between liver fibrosis, mental health, and lifestyle behaviors in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	Keyur Patel	Received

SAT-293	Dietary habits and ultra-processed food consumption in steatotic liver diseases: differences among etiologies and impact on liver histology	Salomé Declerck	Received

WED-294	The use of the FibroScan-AST score and AST to pre-identify metabolic dysfunction-associated steatohepatitis patients with active fibrogenesis in a Phase 1b open-label clinical trial	Mazen Noureddin	Received

SAT-294	The prognostic value of the hepatic venous pressure gradient in severe alcohol-related hepatitis	Andreea Bumbu	Received

FRI-294	Identification of key predictors of significant weight loss in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a multicentre study	Ivan Arcari	Received

THU-294	Resmetirom protects against diet-induced MASLD and reduces atherogenic risk factors in obese Ldlr-/-.Leiden mice	Eveline Gart	Received

SAT-295	Sarcopenia, frailty and growth hormone-insulin like growth factor axis among decompensated and alcohol-associated hepatitis patients	Aishani Wadhawan	Received

WED-295	Unmasking racial disparities of MASLD screening guidelines: underdiagnosis of MASLD among black patients with obesity	Gres Karim	Received

FRI-295	Risk factors for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease	ian yang Liew	Received

THU-295	MiR-4449-merlin-TAZ axis modulates fibrosis progression in MASH	Young-Sun Lee	Received

WED-296	PLIN2 is a specific marker for liver related disease	Giulia Angelini	Received

SAT-296	Prevalence and characteristics of MASLD with greater alcohol consumption (MetALD) in the general population	JOO HYUN OH	Received

THU-296	Identification and assessment of new circulating serological biomarkers for the evaluation of liver disease severity in MASLD patients	Douglas Maya Miles	Received

SAT-297	Recidivism and post-transplant outcomes in patients with alcohol-associated liver disease	Suaka Kagbo-Kue	Received

THU-297	Treatment with the CCR2/CCR5 antagonist Cenicriviroc does not affect MASH and fibrosis development in Ldlr-/-.Leiden mice, translational to clinical phase 3 trial results	Martine C. Morrison	Received

WED-297	Characterization of the evolution of liver elasticity in a real-life population with metabolic dysfunction-associated steatotic liver disease: a prospective study	Joyce Scholtens	Received

WED-298	Myosteatosis is associated with metabolic-associated steatotic liver disease (MASLD) but not liver fibrosis - Results from an Indian cohort	Dinesh Walia	Received

SAT-298	Annual decompensation and death in patients with intermediate severity of alcohol-related liver fibrosis	Sara Tnder Hauskov	Received

FRI-298	Insulin resistance and sarcopenia as comorbid conditions in patients with MASLD	Kateryna Pivtorak	Received

FRI-299	Poor diet quality is associated with higher cardiovascular risk in a cohort of non-cirrhotic Italian MASLD (Metabolic dysfunction associated steatotic liver disease) outpatients	Rusi Chen	Received

WED-299	Utility of ultrasound attenuation imaging in the detection and grading of hepatic steatosis severity as compared to magnetic resonance imaging proton density fat fraction	Ross Apostolov	Received

SAT-299	There is a need to improve retention of people with alcohol-related liver disease in clinical trials: a systematic review and meta-analysis of retention rates in interventional trials	Paula Boeira	Received

THU-299	A 4-week mouse model allows the rapid evaluation of resmetirom and tirzepatide benefits on metabolic dysfunction-associated steatohepatitis	FRANCOIS BRIAND	Received

TOP-300	Clinical, biological and imaging predictors of advanced fibrosis (F3-F4): combined data from multiple therapeutic trials including more than 10,000 patients	Julie Dubourg	Received

TOP-301	Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in steatotic liver disease	Serena Pelusi	Received

THU-302	Suitability of non-invasive tests in the evaluation of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease	Álvaro Yagüe Parada	Received

WED-302	A data-driven approach to determine minimum re-testing interval in persons with metabolic dysfunction associated steatotic liver disease	Callum Wood	Received

SAT-302	Long-term trends in the prevalence of alcohol-related cirrhosis among national U.S. veterans affairs data and territory wide Hong Kong data – an east-west perspective	Robert Wong	Received

FRI-303	Depression as a determinant of metabolic dysfunction-associated steatotic liver disease (MASLD) risk in the Paracelsus 10,000 study	Florian Koutny	Received

THU-303	Elevated SIRT1 levels in arterial hypertension patients with a heightened risk of non-alcoholic fatty liver disease	Anastasiia Radchenko	Received

WED-303	Assessment of the correlation and concordance between ELF and VCTE in the AASLD algorithm for MASLD severity assessment	siham abdelgani	Received

SAT-303	Vitamin D deficiency is associated with advanced liver fibrosis and Type 2 diabetes mellitus in alcohol use disorder	Paola Zuluaga	Received

THU-304	Performance of non-invasive indexes in the assessment of metabolic dysfunction-associated steatotic liver disease	Álvaro Yagüe Parada	Received

WED-304	Accuracy of the recommended algorithm using Fib4 Score and fibroscan to identify MASLD patients with low risk for advanced liver fibrosis in "real world" practice	Eli Zuckerman	Received

SAT-304	Screening of compensated alcohol-related liver disease: efficacy of a holistic approach (hepatology visit, brief intervention and non-invasive test) on alcohol abstinence and relapses	Ares Villagrasa	Received

FRI-304	Assessment of ChatGPT-generated medical arabic responses for patients with metabolic dysfunction–associated steatotic liver disease	Saleh A Alqahtani	Received

WED-305	Comparison of two non-invasive models for advanced fibrosis (AF) detection in patients with type 2 diabetes (T2D) and MASLD using LiverSTAT, FIB-4 and liver stiffness measurement (LSM) with transient elastography (TE)	Mona MUNTEANU	Received

SAT-305	Impact of corticosteroid treatment and clinical risk factors in patients with alcohol-associated hepatitis and clinically significant portal hypertension	Petra Dinjar Kujundic	Received

FRI-305	Lower aspartataminotranspherase activity is associated with dynapenia in middle-aged patients with metabolic dysfunction-associated steatotic liver disease	Anna Sheptulina	Received

THU-306	Study of alternative splicing changes during metabolic dysfunction-associated liver disease development and progression	EIRINI GIANNOUSI	Received

SAT-306	Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury	Lina Hountondji	Received

WED-306	Prevalence of metabolic-dysfunction associated steatotic liver disease among diabetic and non-diabetic patients in a dutch cohort: evaluation of hepatic steatosis and fibrosis using Fibroscan™	Alina Saidi	Received

FRI-306	Insulin resistance in metabolic associated steatotic liver disease and its association with liver-related outcomes: a retrospective study and a nationwide, population-based study	Yang Hyun Baek	Received

TOP-307	The interplay between alcohol consumption and cardiometabolic risk factors in patients with MASLD and MetALD	Yee Huii Yeo	Received

TOP-308	Steatotic liver disease subclasses have prognostic relevance for liver-related outcomes in the general population	Ville Männistö	Received

TOP-309	Identifying patient characteristics associated with the risk of long-term liver and cardiovascular outcomes and high healthcare costs in metabolic dysfunction-associated steatohepatitis: a retrospective cohort analysis using an artificial intelligence mod	Kamal Kant Mangla	Received

TOP-310	Genetic determinants of disease progression in metabolic dysfunction-associated liver disease patients unresponsive to lifestyle intervention: implications for personalized medicine	Yanhua Ding	Received

TOP-311	Subtypes of steatotic liver disease have differing clinical outcomes	Katrina Pekarska	Received

TOP-312	Functional characterization of intrahepatic CD8+ T lymphocytes in patients with severe alcohol-associated hepatitis	Luca Maccioni	Received

TOP-313	Farnesoid X receptor agonist INT-787 protects human liver organoids from alcohol-induced injury	Francesca De Franco	Received

WED-314	Head-to-head comparison of two different ultrasound systems to measure the liver attenuation parameter	Laura De Rosa	Received

SAT-314	Impact of hepatic steatosis on risk of acute liver injury among people with chronic hepatitis B and SARS-CoV-2 infection	Matthew Shing Hin Chung	Received

FRI-314	Plasminogen activator inhibitor-1 (PAI-1) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic-dysfunction associated steatotic liver disease	Marta Guariglia	Received

THU-314	Evaluation of suitable in vitro and in vivo models for metabolic dysfunction-associated steatotic liver disease	Anja Geisler	Received

THU-315	HSD17B13 loss-of-function splice variant delays onset of incident steatotic liver disease and suggests slower progression in established liver disease	Audrey Chu	Received

WED-315	Validation of Fibrosis-6, a novel machine learning non-invasive score to rule out advanced fibrosis and cirrhosis in patients with metabolic-associated fatty liver disease	Mona Ismail	Received

SAT-315	High volume plasma exchange may improve transplant-free survival in patients with severe paracetamol-induced acute liver failure: a case control study	Sébastien LHermite	Received

FRI-315	Metabolic dysfunction associated steatotic liver disease with development of decompensated cirrhosis as long-term complication after distal gastric bypass surgery	Pamela Meyer-Herbon	Received

THU-316	Farnesoid X receptor agonist INT-787 exhibits high intestinal localization	Jennifer Burkey	Received

FRI-316	Influence of reproductive status, synthetic hormone use, and co-medication on serum homocysteine levels and disparities in its contribution to MASLD risk	Ayako Suzuki	Received

WED-316	Gadoxetic acid-enhanced MRI enables detection of fibrosis and inflammation in MASLD/MASH	Edvin Johansson	Received

SAT-316	ß-adrenergic drive impairs small intestinal gut-vascular barrier (GVB): mechanism involved in gut-vascular-barrier dysfunction in acute-on-chronic liver failure (ACLF)	Marco Felber	Received

FRI-317	Clinical outcomes of metabolic liver disease versus non-alcoholic fatty liver disease: a meta-analysis of observational studies	Grazia Pennisi	Received

THU-317	Alcohol-related hepatitis is associated with a distinctive pattern of disordered bile acid metabolism and reduced bile acid transporter expression	Luke Tyson	Received

WED-317	Guided Vibration-Controlled Transient Elastography, a new vibration-guided FibroScan examination	Anne Llorca	Received

SAT-317	Assessment of liver fibrosis in patients taking Methotrexate: long-term outcomes and changes in measurements over time	Ewan H Forrest	Received

THU-318	Deep lipidomic analysis of plasma classifies lipid species capable of segregating septic-shock and predictive of early mortality in severe alcoholic hepatitis (SAH)	GAURAV TRIPATHI	Received

SAT-318	Evaluating the life-saving potential of liver transplantation for acute-on-chronic liver failure with circulatory failure: an observational cohort study	Jun Li	Received

WED-318	Steatotic liver disease in diabetic patients: more serious diabetes mellitus, more serious liver disease	Zülal &304;stemihan	Received

FRI-318	NGFR inhibition by TAT-Pep5 protects mice from acetaminophen-induced liver injury	Laura Kitto	Received

WED-319	AI digital pathology unmasked the "No Change" in conventional pathological assessment of MASLD patients with one year lifestyle intervention in a prospective cohort study	Xiaoxue Zhu	Received

FRI-319	SEMA6B triggers macrophage mediated systemic inflammation in acute-on-chronic liver failure	Jun Li	Received

THU-319	Hepatocyte response to metabolic stress in alcoholic fatty liver leads to sublethal cell toxicity through the perturbation of protein translation-elongation machinery	Takeshi Saito	Received

SAT-319	RECAM-J 2023 – validation of RECAM and development of the japanese version for the diagnosis of DILI	Atsushi Tanaka	Received

SAT-320	Early diagnosis and treatment with Terlipressin for adults with hepatorenal syndrome improves clinical outcomes and reduces healthcare resource utilization	Juan F. Gallegos-Orozco	Received

THU-320	The pan-cyclophilin inhibitor rencofilstat exhibits therapeutic anti-fibrotic effects in human relevant models of alcohol-related liver disease via extracellular matrix remodelling	Una Rastovic	Received

WED-320	Optimizing non-alcoholic fatty liver disease care using mac-2 binding protein glycosylation isomer and correlations with advanced diagnostics	Minh Khue Nguyen	Received

FRI-321	Clinical and molecular features of immune-mediated and drug-induced liver injury	Thais Leonel	Received

WED-321	Association between psoriasis severity and steatosis measured by artificial Intelligence-based algorithm (LIVERFASt)	Mona MUNTEANU	Received

THU-321	Protein source differentially alters the outcome of fecal microbiota transplant in mouse model of alcohol-related liver disease	Shvetank Sharma	Received

SAT-321	A nationwide, multi-center, prospective study of drug-induced liver injury in mainland China	zhang mengmeng	Received

FRI-322	Up-regulation of hyaluronan synthase 2 in hepatocytes contributes to oxaliplatin-induced portal hypertension	Ling Wu	Received

SAT-322	Longitudinal single-cell transcriptomics analyses reveal distinct peripheral immune characteristics linked to ACLF progression	Jun Li	Received

WED-322	Sequential diagnostic approach utilizing FIB-4 and ELF for predicting advanced fibrosis in metabolic-associated steatotic liver disease	Yang Hyun Baek	Received

SAT-323	Establishing a predictive nomogram for 21-day transplant-free survival in drug-induced liver failure	Mengyu Tao	Received

WED-324	Use of FIB4 as a screening test in the bariatric population instead of the NAFLD fibrosis score reduces referral rate to hepatology without reducing identification of significant fibrosis: a retrospective audit	Michael Carbonell	Received

SAT-324	Efficacy of magnesium isoglycyrrhizinate in patients with immune checkpoint inhibitor-related hepatotoxicity	Yang Zhi	Received

FRI-324	Advancing in drug-induced liver injury models development: high content screening in cell-based models derived from skin tissues	Antonio Segovia-Zafra	Received

WED-325	Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction (UDFF) in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease	Federica Tavaglione	Received

SAT-325	Incidence and outcomes of drug-induced liver injury in a large primary care urban area	Anna Pocurull	Received

WED-326	Effects of weight loss on overweight or obese MASLD patients after six months of dieting	Pietro Torre	Received

SAT-326	Immune-mediated liver injury induced by PD-1/PD-L1 checkpoint inhibitors is different from idiosyncratic drug-induced liver injury	Yan Wang	Received

THU-326	Improvement in alcohol-associated hepatitis is characterized by reduction of RNA modification processes	Alastair M Kilpatrick	Received

FRI-326	Multi-omics uncovers spatial remodelling of the hepatic lipidome in acute liver injury	Aleksandra Gruevska	Received

WED-327	Utility of transient elastography in inflammatory bowel disease	Arun Vaidya	Received

THU-327	Exploring the AhR molecular pathways to improve gut microbiota and liver injury in alcohol-associated liver disease	Wanchao Hu	Received

FRI-327	Plasma multi-omic reveals dysregulated gut arbitrated increase in bacterial peptides and metabolites predictive of poor outcomes in acute liver failure	SUSHMITA PANDEY	Received

SAT-327	The combination of s-ademethionine with Bifidobacterium infantis 35624 inhibits oxidative stress as a risk factor for cytostatic-induced liver injury	Igor Skrypnyk	Received

TOP-328	Single-nucleus RNA sequencing of the liver identifies predictive markers to corticosteroid treatment in patients with severe alcohol-related hepatitis	Lukas Van Melkebeke	Received

TOP-329	Integrated plasma multi-omics analysis classifies key mycobiome, microbiome and metabolome changes linked to development of poor outcome in severe alcoholic hepatitis	GAURAV TRIPATHI	Received

WED-330	Description of a cohort of patients with metabolic dysfunction-associated steatotic liver disease followed at an urban liver centre (Toronto liver centre), high prevalence of extrahepatic conditions	Magdy Elkhashab	Received

THU-330	Complement protein signatures in patients with alcohol-associated hepatitis	Laura Nagy	Received

FRI-330	MiRNA/mRNA network topology in acute-on-chronic liver failure identified miR-503-5p as a regulatory hub of lymphocytes activation through antigen-presentation suppression	Jun Li	Received

SAT-331	Anticancer drugs are the first cause of drug-induced liver injury in the REFHEPS network	lucy meunier	Received

THU-331	The humoral profile of immunoglobulins specific for microbiota antigens stratifies the severity of patients affected by alcohol-related liver disease and predicts their 90-d mortality	Antonella Putignano	Received

WED-331	Subclinical myocardial fibrosis is related to disease severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)	Puria Nabilou	Received

WED-332	FAST and Agile – the MASLD Drift: validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven MASLD patients of prevalent caucasian origin	Madalina-Gabriela Taru	Received

SAT-332	Frequency and clinical features of tamoxifen-induced liver injury	Masayuki Ueno	Received

THU-333	Novel mechanism of golgiphagy in hepatocytes and the protective impact of hydroxychloroquine on alcohol-induced liver damage and steatosis	Armen Petrosyan	Received

SAT-333	Efficacy of magnesium isoglycyrrhizinate as add-on therapy to glucocorticoids in immune checkpoint inhibitor-related hepatotoxicity	Yinuo Dong	Received

WED-333	Association of clinical and biochemical parameters and polygenic risk score in a metabolic steatosis population of southern Italy	Benedetta Maria Motta	Received

FRI-333	Sibiriline, an inhibitor of regulated necrosis, protects mice against Acetaminophen-induced liver injury, alone or in combination with N-acetyl-cysteine	Mélanie Simoes Eugenio	Received

THU-334	Supplementation of the amino acid L-arginine attenuates the onset of alcohol-related liver diseases	Anja Baumann	Received

SAT-334	Histopathological findings in liver biopsies of patients affected by multiple sclerosis undergoing disease-modifying therapies and pulse methylprednisolone	Federica Pedica	Received

WED-334	Comparison of Hepatoscope® and FibroScan® for non-invasive assessment of hepatic steatosis and fibrosis among mexican immigrant adults along the southern Arizona United States/Mexico border	Edgar Villavicencio	Received

WED-335	Fibrosis detection in MASLD: A two steps comparative study	Carmen Lara-Romero	Received

SAT-335	Pathological dynamics and clinical implications of hepatitis in cancer patients undergoing immune checkpoint inhibitor	Ryo Izai	Received

THU-335	The new nomenclature of steatosic liver disease identifies different risk trajectories for liver-related complications	Bocquillon Adrien	Received

FRI-335	An exploration of plasma neurofilament protein as a marker of neuronal damage in acute liver failure	Marilena Stamouli	Received

WED-336	RESIST-NASH: a regional network for identification and referral of masld patients at risk for liver fibrosis	Grazia Pennisi	Received

SAT-336	Monocytes/macrophages imbalance in chronic drug-induced liver injury: potential candidates for disease pathogenesis	Zherui Liu	Received

WED-337	The non-invasive assessment of liver fibrosis in metabolic dysfunction associated steatotic liver disease (MASLD) in the chinese population: a scoping review	Lai Wei	Received

SAT-337	Serum levels of IgA inform on the transcriptomic architecture of the liver and predict hepatocellular carcinoma in chronic viral hepatitis patients	Nicolaas Van Renne	Received

WED-338	Transcriptomic analysis reveals novel biomarkers and PI3K-AKT signaling pathway findings of at-risk metabolic dysfunction-associated steatohepatitis	Wen Wang	Received

THU-338	Portal neutrophils exhibit an activated phenotype in alcohol-related liver disease	Sara Reinartz Groba	Received

FRI-338	Obeticholic acid promotes the hepatic ductular reaction via hepatocyte-mediated HMGB1 by disrupting autophagosome-lysosome fusion in cholestasis	Jie Wang	Received

SAT-338	Using retrieval augmented generation to increase large language models accuracy: a proof-of-concept pipeline on european hepatitis C virus (HCV) guidelines	Mauro Giuffre	Received

THU-339	Abstinence induces site-specific metabolomic alterations in resolution from alcohol-related liver disease	NUPUR SHARMA	Received

FRI-339	Obeticholic acid promotes the hepatic ductular reaction via macrophage-mediated Relb-TNFSF14 signaling in cholestasis	Jie Wang	Received

SAT-339	Sequential administration of siRNA with an mRNA encoding clearance profile associated variants of HBsAg exhibits significant antiviral activity in AAV/HBV mouse model	Aditi Deshpande	Received

WED-339	MASLD patients with liver cirrhosis have an increased early cardiovascular risk measured by epicardial adipose tissue	Marta Hernández Conde	Received

SAT-340	Human intestinal enteroids as a new in vitro model to study hepatis E virus	Nanci dos Santos Ferreira	Received

THU-340	Multiomics landscape of alcohol detoxification and the role of PNPLA3 genotype	Anna Karl	Received

WED-340	Agreement between two-dimensional shear wave elastography and transient elastography in metabolic dysfunction-associated steatotic liver disease: implications for primary care screening	Shelley Keating	Received

SAT-341	Discovery of a pan-genotypic hepatitis E virus replication inhibitor	Xin Zhang	Received

THU-341	Mouse models of MetALD and metabolic dysfunction-associated steatohepatitis elicit similar patterns of liver injury	Naomi Lange	Received

FRI-341	Clusterin deficiency exacerbates cholestatic liver disease through ER stress and NLRP3 inflammasome activation	Hye-Young Seo	Received

WED-341	EUS-guided assessment of steatotic liver disease in bariatric surgery patients	Paula Fernandez Alvarez	Received

SAT-342	PegIFNa treatment in NUC-suppressed HBV/HDV-infected mice with high numbers of HDV-monoinfected cells reduces HDV infection below the limit of quantification	Annika Volmari	Received

FRI-342	Visualisation of intrahepatic activation of coagulation and its contribution to disease progression in mice with acetaminophen-induced acute liver injury	Fien von Meijenfeldt	Received

WED-342	Can we define MASLD in liver outpatient clinics? Keeping up with the changing nomenclature	Mercy Karoney	Received

SAT-343	Impact of hepatitis C virus direct acting antivirals on hepatocellular carcinoma evolution	Stanislas Pol	Received

THU-343	Dissecting metabolic dysfunction-associated steatotic liver disease with increased alcohol intake (MetALD): clinical and molecular insights and classification	Jun Liu	Received

FRI-343	APAP induced liver damage is prevented by activation of PPAR-gamma and PPAR-alpha	Paul Gomez-Jauregui	Received

WED-343	Transducer reproducibility in liver ultrasound-derived fat fraction measurements	Reinhard Kubale	Received

TOP-344	Personalized prediction of spontaneous recovery in acute liver failure listed for liver transplantation	Xun Zhao	Received

TOP-345	Clinical and HLA associations of fluoroquinolone induced liver injury: results from the drug induced liver injury network (DILIN)	JAWAD AHMAD	Received

TOP-346	Therapeutic plasma exchange in Amatoxin associated acute liver failure – results from an interim analysis of the Amanita-PEX study	Dr. Bahar Nalbant	Received

THU-347	Minibioreactor arrays (MBRAs) to model microbiome response to tryptophan and alcohol in the context of alcohol-associated liver disease (ALD)	Wanchao Hu	Received

FRI-347	HYX1-derived exosomal let-7c-5p protects against acute liver failure by inhibiting SLC11A2-mediated ferroptosis	Yu Chen	Received

WED-347	Diagnosis of advanced liver fibrosis: the synergy of open data, synthetic data generation, CatBoost, and feature engineering	Athanasios Angelakis	Received

SAT-348	Hepatitis B virus-induced collagen VI expression by hepatocytes contributes to liver fibrosis by promoting stellate cell activation	Zakaria Boulahtouf	Received

FRI-348	Endogenous Annexin A1 has a protective effect on the liver in a diabetic mouse model	Diego Dias dos Santos	Received

WED-348	High prevalence of liver fibrosis and cirrhosis among cohort of patients referred to an urban liver centre for evaluation of metabolic dysfunction-associated steatotic liver disease (utility of transient elastography)	Magdy Elkhashab	Received

TOP-349	Plasma lipidomics and fungal peptide-based community analysis identifies signatures of severity and early mortality in acute liver failure	Neha Sharma	Received

TOP-350	DNA differential methylation as a potential drug-induced liver injury biomarker and genome-wide DNA methylation functional analysis	Marina Villanueva	Received

TOP-351	A therapeutic strategy to target CD47 using SIRP alpha expressed extracellular vesicles derived from engineered mesenchymal stem cells to promote liver regeneration following severe injury	Seohyun Kim	Received

TOP-352	Serum proteomics can help identify new prognostic biomarkers in adults with acute liver failure	Katharina Remih	Received

TOP-353	An mRNA vaccine exhibits anti-viral activity in mouse model of persistent hepatitis B infection	Aditi Deshpande	Received

TOP-354	Potent and sustainable HBsAg clearance by a liver-targeting PD-L1 siRNA in mice	Zhiwei Yang	Received

TOP-355	T cells expressing HBV-specific chimeric antigen receptors harboring a Fab fragment control HBV infection in mice	Zhe Xie	Received

TOP-356	Combination treatment of a TLR7/8 dual agonist with an antisense oligonucleotide bepirovirsen and entecavir leads to additive HBsAg decline in the AAV-HBV mouse model	Ke Qiu	Received

TOP-357	Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs	Jin Hong	Received

TOP-358	Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles	Yannick Debing	Received

TOP-359	Development of a replication-competent Vesicular Stomatitis Virus (VSV) vector for therapeutic hepatitis B vaccination	Jinpeng Su	Received

TOP-360	Hepatitis B Spliced-generated Protein (HBSP): a key factor of viral escape	Pierre Bablon	Received

WED-361	Dosing with the Capsid Assembly Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects Results in Potent Antiviral Effects Including Suppression of HBV DNA/RNA and Declines in HBcrAg Levels	Kosh Agarwal	Received

SAT-361	Generation and characterization of hepatitis D virus specific antisera with respect to the recognized epitopes	Keerthihan Thiyagarajah	Received

FRI-361	Burden of liver disease progression in patients with chronic HDV infection: a population-based study for France	Lucia Parlati	Received

THU-362	Ravidasvir in combination with sofosbuvir for 12 or 24 weeks achieved high sustained virological response rates in genotype 3 chronic hepatitis C without or with compensated liver cirrhosis	Isabela Ribeiro	Received

WED-362	Rapid hepatitis B surface antigen reduction in chronic hepatitis B virus infection: preliminary results from a phase ? b study evaluating multiple ascending doses of HT-102, a neutralizing antibodies against hepatitis B surface antigen in chronic hepatiti	Shanzhong Zhang	Received

FRI-362	Hepatitis B surface antigen (HBsAg) seroclearance following discontinuation of nucleos(t)ide analogues (NA) treatment has comparable durability to HBsAg seroclearance achieved during NA therapy	Terry Cheuk-Fung Yip	Received

WED-363	Promising preliminary data on preclinical efficacy with an innovative plasmid-launched live attenuated virus vaccine for chronic hepatitis B	Frederik Pauwels	Received

THU-363	Validation of a modified pediatric formulation of Sofosbuvir and Daclatasvir in genotype-4 HCV-infected children weighing 17-35 Kg	Manal El-Sayed	Received

SAT-363	Hepatocellular carcinoma development post hepatitis C virus cure is associated with distinct changes in the dynamics of the soluble inflammatory milieu	Moana Witte	Received

FRI-363	Association between metabolic dysfunction, severity of liver fibrosis and fibrosis progression in patients with chronic hepatitis B – an individual patient data meta-analysis	Lisa van Velsen	Received

WED-364	High-dimensional analysis of flow cytometry data reveals differences in post-treatment frequencies of naïve B cells, CD56dim natural killer cells, and terminally differentiated effector memory CD8+ T cells in responders versus non-responders to bepirovirs	Jennifer M. Singh	Received

FRI-364	Baseline and reduction at 1 year of hepatitis B surface antigen level predicts functional cure and low HBsAg titer: A long-term kinetics of hepatitis B surface antigen	Soon Kyu Lee	Received

THU-364	Modeling suggests that undetectable HCV at week 2 of DAA therapy could identify patients for shorter treatment duration	Harel Dahari	Received

SAT-364	Mathematical modeling of hepatitis B and D viral kinetics during coinfection in humanized mice suggests differences in their infectivity	Harel Dahari	Received

FRI-365	Limited use of established risk scores for the prediction of hepatocellular carcinoma in patients with chronic hepatitis D virus infection	Robin Iker	Received

WED-365	Extended treatment of HBeAg+ CHB subjects with the Capsid assembly modulator ALG-000184 with or without Entecavir is associated with reductions in viral markers and favorable anti-HBeAb trends	Man-Fung Yuen	Received

THU-365	Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry	Michael Huang	Received

SAT-365	Hepatitis B virus mutations associated with hepatocellular carcinomas are regulated by HLA genotype	Masaya Sugiyama	Received

WED-366	Characterization of BJT-778, an anti-HBsAg neutralizing monoclonal antibody for treatment of hepatitis B virus and hepatitis D virus infections	Hilario Ramos	Received

FRI-366	HBV DNA thresholds and immune tolerance: unveiling new insights from cross-sectional hepatic histology data in hepatitis B	Tingyu Zhang	Received

THU-366	Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: Data from the German Hepatitis C-Registry (2016 - 2022)	Marianna Schwenken	Received

SAT-367	HBV promotes viral replication and autophagic secretion through HBx down-regulation of HDAC6 expression	Lili Wu	Received

THU-367	Effectiveness and safety of direct-acting antivirals in the treatment of elderly people infected with HCV	Michal Brzdek	Received

WED-367	Viral sequence analysis of chronic hepatitis B (CHB) patients treated with the silencing RNA (siRNA) JNJ-3989 in the REEF-1 and REEF-2 clinical studies	Thierry Verbinnen	Received

FRI-367	Prediction of hepatocellular carcinoma risk and liver-related events in chronic hepatitis D, an international retrospective cohort study (RIDE)	Lesley Patmore	Received

TOP-368	Detection of HBV-, HDV- and human mRNAs in archival FFPE tissues by spatial transcriptomics	Sangeetha Mahadevan	Received

TOP-369	HEV replication and genomic diversification in the human kidney	André Gömer	Received

WED-370	Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: indirect evidence from B-together peripheral longitudinal biomarker analysis	Shilpy Joshi	Received

FRI-370	Bulevirtide efficacy and safety in chronic hepatitis delta patients on liver transplant waiting list	Magdalena Meszaros	Received

SAT-370	PRO-C3 determined active fibrogenesis is a predictor of liver-related outcomes in patients with chronic hepatitis C	Emilie Skovgaard	Received

THU-370	Hepatocellular carcinoma may be a viral reservoir during treatment of hepatitis C with direct-acting antivirals	Mário Jorge Silva	Received

FRI-371	Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy	Fabien Zoulim	Received

SAT-371	No amino acid substitution in HBV PreS1, HDAg, or NTCP associated with suboptimal response to bulevirtide in combination with pegylated interferon alfa-2a treatment in participants with chronic hepatitis delta: results from MYR204 a phase 2b study	Yang Liu	Received

THU-371	Impact of a simplified diagnosis-monitoring strategy on Glecaprevir/Pibrentasvir (G/P) treatment initiation and response in patients with chronic hepatitis C virus(HCV) infection receiving opioid substitute therapy in Israel – a real world evidence	Eli Zuckerman	Received

WED-371	Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment	Karen Sims	Received

WED-372	Downregulation of soluble FASLG as a potential mechanism of enhanced immune-related clearance of infected hepatocytes induced by JNJ-73763989 in HBeAg-negative virologically suppressed chronic hepatitis B patients	Simon Verheijden	Received

THU-372	Point of care hepatitis C screening and treatment among people who use drugs in new york city addiction centers: barriers and opportunities	Jessica Siguencia	Received

FRI-372	The effect of age and pregnancy on transition into Immune Active disease in Immune Tolerant patients – a retrospective cohort study of 245 patients	Edo Dongelmans	Received

SAT-373	Intrahepatic sodium taurocholate co-transporting polypeptide gene transcript and membrane-localized protein expression changes in chronic hepatitis D patients following 48 weeks of treatment with Bulevirtide	Wildaliz Nieves	Received

THU-373	Quality of etiotropic therapy efficasy of chronic hepatitis C patients in accordance of toll-like receceptor 4 +3725G/C gene polymorfisms variety	Tetiana Bevz	Received

FRI-373	Impact of pregnancy on global and HBV-specific B-cell immunity	Anna Pocurull	Received

WED-374	Safety, tolerability, and pharmacokinetics of BJT-778, a monoclonal antibody for treatment of chronic hepatitis B and chronic hepatitis D, following single ascending doses in healthy volunteers	Edward Gane	Received

THU-374	Description of age, sex, and characteristics of hepatitis C patients in the SVR10K study: a real-world SOF/VEL analysis performed across five global regions	Candido Hernandez	Received

FRI-374	The UK experience of liver transplantation for HBV: excellent clinical outcomes despite a significant burden of HBV/Delta disease and wide variation in hepatitis B immunoglobulin prophylaxis practices – time for a consistent approach?	Almuthana Mohamed	Received

SAT-374	IL-15 plus anti-PDL-1 restores CD8 T-cell response against core but not against polymerase in chronic hepatitis B with extreme exhaustion-associated factors	Henar Calvo Sánchez	Received

FRI-375	The coinfection of hepatitis C virus or human immunodeficiency virus in chronic hepatitis B in South Korea: A population-based study using the Korean Health Insurance Review & Assessment Service database	Jae Yoon Jeong	Received

WED-375	VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels	Man-Fung Yuen	Received

THU-375	When glecaprevir/pibrentasvir ultra-short therapy is enough to eradicate HCV infection	ALBERTO GRASSI	Received

SAT-375	Proteomic analysis of plasma exosomes: a novel method to identify potential therapeutic targets for chronic hepatitis B	Meng Zhao	Received

FRI-376	The impact of alanine aminotransferase fluctuation on the hepatocellular carcinoma risk in chronic hepatitis B patients	Youngsu Park	Received

WED-376	Tobevirbart (VIR-3434), a monoclonal antibody, resistance analysis in participants with chronic HBV: Results from a Phase 1 single dose study	Andrea Cathcart	Received

SAT-376	Hepatitis C virus specific CD8+ T cells of patients with acute and chronic HCV infection display high expression of CD96 and other co-inhibitory molecules	Maximilian Knapp	Received

WED-377	Preclinical profiling of ABI-6250, a novel orally bioavailable small-molecule therapeutic candidate for the treatment of chronic hepatitis D	Marc P. Windisch	Received

SAT-377	CRISPR-Cas13b-mediated suppression of hepatitis B surface antigen – pre-clinical investigations of a new therapeutic approach	Laura McCoullough	Received

FRI-377	Decline of Serum HBV RNA level During the First Week of Nucleos(t)ide Analogues Therapy Is Associated with Liver Injury and More Efficient Clearance of Hepatitis B Virus	Liandong Wu	Received

WED-378	Association of baseline characteristics and plasma ALG-001075 to HBsAg responses in HBeAg+ CHB subjects following ALG-000184±ETV treatment	Kha Le	Received

SAT-378	Association between occult hepatitis B virus infection and parenchymal renal cell carcinoma	Daniele Lombardo	Received

FRI-378	Effect of diabetes on the risk of fibrosis progression in patients with chronic hepatitis B	Mi Na Kim	Received

THU-378	Prediction of outcomes in patients with HCV compensated liver cirrhosis after SVR: results from 5-years of follow-up	Luisa Ranieri	Received

WED-379	Intrahepatic changes in immunologic and virologic markers during siRNA JNJ-73763989 (JNJ-3989) based treatment of chronic hepatitis B (CHB) patients: imaging mass cytometry (IMC) analyses from the INSIGHT study	Simon Verheijden	Received

THU-379	Artificial intelligence model for predicting liver-related events in non-cirrhotic patients after successful treatment by direct-acting antivirals for chronic hepatitis C	Seung up Kim	Received

SAT-379	Immune checkpoint proteins are associated with persistently elevated liver stiffness after successful HCV therapy in people with HIV	Rubén Martín Escolano	Received

FRI-379	Feasibility of aMAP combined with liver stiffness assessed using transient elastography for prediction of hepatocellular carcinoma development in patients with chronic hepatitis B	Hye Yeon Chon	Received

FRI-380	HBV-specific T cell specificity and functionality can be influenced by stage of chronic HBV disease, antigen levels and age	An De Creus	Received

SAT-380	Burden of acute hepatitis A in France - a 10-year nationwide study	Charlotte Mouliade	Received

THU-380	Individualized intervals for streamlined directly observed therapy in PWIDs - a unique approach to continue HCV microelimination throughout the COVID19 pandemic	Caroline Schwarz	Received

WED-381	A double-blind, placebo-controlled, single-ascending dose phase ?a study to evaluate the safety, tolerability, and pharmacokinetics of HT-102, a neutralizing antibodies against the hepatitis B surface antigen in Chinese healthy volunteers	Shanzhong Zhang	Received

THU-381	Prognostic implications of liver stiffness impairment after HCV cure in cACLD patients	Monica Pons	Received

FRI-381	Detection of functional HBV-specific CD8+ response is associated with significant decrease of HBsAg level after treatment withdrawal in eAg(-)chronic hepatitis B	Henar Calvo Sánchez	Received

SAT-381	Low diversity of the TCRbeta repertoire in patients with chronic hepatitis D	Maria Francesca Cortese	Received

SAT-382	Ethanol exposure exacerbates HBV-infection pathogenesis: possible mechanisms and treatment targets	Natalia Osna	Received

THU-382	Lead-in cohort results from a phase 2 study of a novel 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection	Alina Jucov	Received

WED-382	Modeling dual antiviral activity of lonafarnib to explain hepatitis D virus RNA negativity 24 weeks after end of therapy despite RNA positivity at end of therapy: The D-LIVR study	Harel Dahari	Received

FRI-383	Unique characteristics and risk of liver-related events among individuals with hepatitis D virus infection with and without concurrent hepatitis C virus infection: a United States administrative claims analysis	Laura Telep	Received

SAT-383	Rapid analysis of HBV-specific T cell secretomes reveals distinct antiviral immune profiles among chronic HBV patients	Nina Le Bert	Received

WED-383	Antiviral efficacy of REP 2139-Mg and effects on HVPG in HDV/HBV coinfected patients with cirrhosis and portal hypertension non-responding to previous bulevirtide treatment	Michael Schwarz	Received

THU-383	Predictive performance of HCC risk scores in chronic hepatitis C patients with advanced fibrosis after achieving SVR: real-world experience from a tertiary UK centre	Riham Soliman	Received

TOP-384	Macrophage-augmented organoids recapitulate the complex pathophysiology of viral diseases affecting the liver and devise advanced treatment strategies	Kuan Liu	Received

TOP-385	Evaluation of liver fibrosis in patients with advanced chronic liver disease due to hcv after 6 years of sustained viral response. study with paired biopsies at 3 and 6 years	Lidia Canillas Alavés	Received

WED-386	A double-blind, placebo-controlled, single-ascending dose phase ?a study to evaluate the safety, tolerability, and pharmacokinetics of HT-101, an investigational small interfering ribonucleic acid targeting hepatitis B virus in Chinese healthy subjects	Shanzhong Zhang	Received

FRI-386	Optimizing HDV diagnosis algorithm in Israel: reflex testing, prevalence of HDV seropositive individuals identified in Maccabi HealthCare services and assessment of three commercially available HDV viral load assays	Yael Gozlan	Received

SAT-386	Characterization of intrahepatic immune microenvironment in liver biopsies across different phases of untreated HBeAg-negative patients	Maria Stella Franzè	Received

THU-386	Renin-angiotensin inhibitor intake is associated with improved survival in patients with chronic hepatitis C viral infection following SVR – data from the german hepatitis C-registry (DHC-R)	Yvonne Serfert	Received

SAT-387	Use of capillary Samples for hepatitis B Virus Load Quantification Using Xpert (R) HBV	Gora LO	Received

THU-387	Safety and efficacy of two pangenotypic direct acting antivirals (sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) for the treatment of hepatitis C in children	Ewa Talarek	Received

FRI-387	Similarly low risk of hepatocellular carcinoma and cirrhotic complications in patients in the HBeAg-negative indeterminate phase compared with chronic infection	vicki wing-ki hui	Received

WED-388	Safety, tolerability, and hepatitis B surface antigen reduction of HT-101 in chronic hepatitis B patients: preliminary results from a phase?b study	Shanzhong Zhang	Received

SAT-388	Comprehensive analysis of CHB concurrent with NAFLD: a proteomics report based on clinical liver samples	Xin Tong	Received

THU-389	Sustained virological response after early discontinuation of HCV treatment	Robert Flisiak	Received

WED-389	Pharmacokinetics and safety of the monoclonal antibody tobevibart (VIR-3434) administered as monotherapy or in combination with the small interfering RNA elebsiran (VIR-2218) in cirrhotic participants with mild hepatic impairment	Sneha Gupta	Received

SAT-389	HBV and HBsAg strongly reshape the phenotype, function and metabolism of DCs according to patients´ clinical stage	Zuzana Macek Jilkova	Received

FRI-389	Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B	Robert Wong	Received

FRI-390	Off-treatment outcomes after discontinuing tenofovir-based treatment in hepatitis B e antigen-positive and hepatitis B e antigen-negative patients with chronic hepatitis B virus	Maria Buti	Received

WED-390	Efficacy and safety of tenofovir alafenamide fumarate in preventing HBV vertical transmission in high maternal viral load: a multi-centre, prospective cohort study	Xiaoping Tang	Received

THU-390	Achieving HCV elimination in underserved populations - an austrian initiative for HCV care for homeless people without medical insurance	Caroline Schwarz	Received

SAT-390	Nonclinical phenotypic evaluation of clinically identified baseline and treatment-emergent hepatitis B Virus variants that contain single nucleotide polymorphisms in the bepirovirsen binding site	Christine Livingston	Received

THU-391	Impact of hepatitis C cure on outcomes for patients undergoing curative therapy for hepatocellular carcinoma	Alex Wynne	Received

SAT-391	Investigation of HBV cccDNA Methylation by Bisulfite sequencing for therapeutic targeting in liver biopsies from hepatitis B patients	Purnima Tyagi	Received

FRI-391	Relapse incidence and severe flares in chronic hepatitis B patients with lymphoma post rituximab-based chemotherapy versus HBeAg-negative hepatitis B patients without cancer after nucleos(t)ide analogue cessation	Yen-Chun Liu	Received

WED-391	Long-term virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy for up to 120 weeks: a retrospective multicenter european study (save-d)	Elisabetta Degasperi	Received

WED-392	Improvement in liver histology is observed in most patients with chronic hepatitis delta after 48 weeks of bulevirtide monotherapy	Pietro Lampertico	Received

FRI-392	Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV mono-infection, that parallels HDV replicative and cytolytic activity	Lorenzo Piermatteo	Received

SAT-392	Perturbed pathways of lipid metabolism in patients with chronic hepatitis B infection after cessation of long term nucleos(t)ide analogue	Lungyi Mak	Received

FRI-393	Healthcare resource utilisation and costs of hepatitis delta virus infection vs hepatitis B virus monoinfection across disease states among hospitalised adults in Italy	Chong Kim	Received

WED-393	Association between post-treatment ALT elevation and subsequent hepatitis B surface antigen seroclearance in chronic hepatitis B patients stopping nucleos(t)ide analogue therapy	Yao-Chun (Holden) Hsu	Received

SAT-393	Profile of miRNAs in chronic hepatitis D patients with or without viral replication	Maria Francesca Cortese	Received

SAT-394	HBV genotyping: grasping a new window of opportunity?	Marion Delphin	Received

THU-394	Improvement of hepatitis C virus care cascade by In-hospital Reflex tEsting ALarm-C (REAL-C) model	Jonggi Choi	Received

WED-394	Hepatic flares after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B: results from the Nuc-Stop study	Marte Holmberg	Received

FRI-394	High burden of cirrhosis and increasing response rates to bulevirtide-based regimens: insights from the austrian prospective hepatitis D registry	Michael Schwarz	Received

WED-395	Undetectable hepatitis delta virus RNA at the end of treatment with bulevirtide and pegylated interferon alpha-2a is an important predictor of 48 weeks sustained virologic response in chronic hepatitis delta	Fabien Zoulim	Received

FRI-395	HDV infection in Israel: epidemiology and co-morbidities	hisham sholy	Received

SAT-395	ROS-dependent activation of JAK2/STAT3 pathway contributes to HBV-induced liver inflammation	Rui Song	Received

THU-395	Is hepatitis C screening based on risk factors enough in primary care setting?	Elena Vargas-Accarino	Received

THU-396	HCV patients achieving sustained virologic response after direct-acting antiviral therapy may still face adverse clinical outcomes: analysis of gene enrichment, marker expression, and clinical outcomes	Daniel Millian	Received

WED-396	Changes in metabolic parameters after switching from tenofovir disoproxil fumarate to tenofovir alafenamide among chronic hepatitis B patients: a randomized, open-label controlled trial	Titinan Veerachit-O-larn	Received

FRI-396	Risk of hepatocellular carcinoma decreases after antiviral therapy-induced HBsAg seroclearance	Han Ah Lee	Received

SAT-396	Differences in the intrahepatic expression of immune checkpoint molecules on T cells and natural killer cells in chronic HBV patients	Zuzana Macek Jilkova	Received

SAT-397	Transcriptomic analysis and high-throughput hepatitis B virus integration sequencing of HepaD38 cells	Cristina Musolino	Received

WED-397	Tenofovir-based antiviral therapy reduces long-term incidence of hepatocellular carcinoma in chronic hepatitis B patients	Isabel Haber	Received

FRI-397	A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B	Moon Haeng Hur	Received

THU-397	Long-term histological fibrosis evolution following sustained virological response after hepatitis C-recurrence in liver-transplanted patients	Tibo Lemmens	Received

THU-398	Metabolic factors predict significant liver fibrosis in people who use drugs (PWUD) and general population with HCV infection. Time to re-consider the follow-up strategy in chronic hepatitis C patients	Hariklia Kranidioti	Received

WED-398	HBsAg loss in inactive chronic hepatitis B carriers is dependent on level of qHBsAg and interferon response: a randomised control trial	Seng Gee Lim	Received

FRI-398	Targeted capture single-cell sequencing provides new insights into persistent hepatitis B virus (HBV) infection	Yanfang Huang	Received

THU-399	Burden of extrahepatic manifestations after HCV cure: assessing the effect of IFN versus DAA-induced SVR in a large population-based cohort in British Columbia, Canada	Dahn Jeong	Received

WED-399	The composition of HBsAg along with HDV-RNA predicts virological response in chronic hepatitis delta patients treated with bulevirtide for 48 weeks	Stefano DAnna	Received

FRI-399	Hepatitis B core-related antigen is a good predictor for high risk of mother to child transmission in chronic hepatitis B	Ivana Carey	Received

SAT-399	Immune profiling of HBsAg-specific B cells in CHB patients with HBsAg loss	Yifei Guo	Received

TOP-400	Impact of bulevirtide given with or without nucleos(t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection	Pietro Lampertico	Received

TOP-401	Improvement of liver stiffness during nucleo(s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk	Lesley Patmore	Received

SAT-402	Bemnifosbuvir is a potent HCV NS5B inhibitor with a favorable antiviral profile and high resistance barrier	Qi Huang	Received

FRI-402	The unique role of hepatitis B virus enhancer 1 in unevenly activating preS1 and preS2 promoters of integrated HBV DNA which impacts HBsAg secretion efficiency	Fengmin Lu	Received

THU-402	Higher cardiovascular burden in people living with HIV (PLWH) with metabolic syndrome and history of HCV infection	Alessia Siribelli	Received

WED-402	Risk of hepatocellular carcinoma after curative treatment when switching from Tenofovir Disoproxil Fumarate or Entecavir to Tenofovir Alafenamide: a real-world multicenter cohort study	Hyunjae Shin	Received

WED-403	HEllenic multicenter ReAl-life CLInical Study for bulevirtide therapy in chronic hepatitis D (HERACLIS_BLV_D)	Margarita Papatheodoridi	Received

THU-403	Liver fibrosis and steatosis in children after effective treatment of chronic hepatitis C using direct acting antivirals	Anna Dobrzeniecka	Received

FRI-403	Evaluation of a novel hepatitis B DNA test from fingerstick capillary blood at the point-of-care as a tool to enhance clinical management	Behzad Hajarizadeh	Received

SAT-403	Vitamin D supplementation accelerated reduction of HBsAg levels in patients with chronic hepatitis B requiring treatment and in inactive carrier phase	Thitaporn Roongrawee	Received

THU-404	Impact of hepatitis C treatment on mortality among liver cancer patients in Georgia - 2015-2022	Anna Khoperia	Received

SAT-404	The Lipidome in phenotyping hepatitis B infection (´LiPHe-B´): preliminary results from our pilot study	Marion Delphin	Received

WED-404	Comparable outcomes between Besifovir and other antiviral therapies in hepatocellular carcinoma development among patients with chronic hepatitis B	Jae Seung Lee	Received

FRI-404	To establish the threshold for transient elastography indicating advanced fibrosis in patients with chronic hepatitis B and hepatic steatosis	Jie Li	Received

FRI-405	Heterogeneity in the diagnostic performances of HDV-RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study	Romina Salpini	Received

SAT-405	Differential expression and sequence variants of sodium taurocholate cotransporting polypeptide (NTCP) do not affect HDV inhibition by Bulevirtide (BLV)	Roberto Mateo	Received

THU-405	Analysis of a decentralized model interdisciplinary for the elimination of HCV in vulnerable population in the province of Huelva (Spain). To continue advancing in the elimination of hepatitis C, it is necessary to establish a clearly defined integrated c	Gema Romero	Received

WED-405	Tenofovir disoproxil fumarate and tenofovir alafenamide interruption in hepatitis B and human immunodeficiency virus co-infected individuals in the United States: monitoring practices and incidence of hepatitis B reactivation or hepatitis flare	Laurence Brunet	Received

WED-406	DARING-B study: 5-year outcomes after nucleos(t)ide analogue (NA) cessation in Caucasian non-cirrhotic patients with HBeAg-negative chronic hepatitis B (CHBe-)	Margarita Papatheooridi	Received

THU-406	Knowledge, perceptions and barriers to the diagnosis and treatment of hepatitis C among persons who inject drugs: findings from the Educate-Test-Treat (ETT) programme in Singapore	Shann Long	Received

SAT-406	HBV dominance is associated with a distinct inflammatory milieu in HBV/HCV coinfection	Carlos Oltmanns	Received

FRI-406	Real world outcomes of hepatitis delta patients with mild or moderate fibrosis	Sabela Lens García	Received

FRI-407	Screening rates, prevalence, and natural history of hepatitis B/delta virus co-infection vs. hepatitis B mono-infection: data from a large US integrated healthcare system	Varun Saxena	Received

WED-407	Characterization of hepatitis D virus RNA and hepatitis B surface antigen kinetics during pegylated interferon-alpha monotherapy: The D-LIVR study	Ohad Etzion	Received

SAT-407	Long-term sustained decline of anti-HCV neutralizing antibodies in HIV/HCV-coinfected patients after therapy-induced HCV clearance	Daniel Sepúlveda-Crespo	Received

THU-407	A new pattern for hepatitis C management in hospital: establishment and effectiveness verification	Siheng Zhu	Received

FRI-408	Statins in untreated chronic HBV link with improved survival, liver outcome and inflammation: a large multicenter retrospective real-world cohort study	Mohammed Suki	Received

SAT-408	Molecular and functional analysis of a hepatitis B virus genotype C infection in a vaccinated individual	Maëlenn Païline Delcourt	Received

WED-408	Factors influencing HBsAg clearance in children with chronic hepatitis B undergoing antiviral therapy: significance of age at treatment onset and HBeAg titer dynamics	Byung Ho CHOE	Received

THU-408	The prognostic influence of toll-like receptor 4 +3725G/C gene polymorphism on biochemical profile among chronic HCV hepatitis patients	Tetiana Bevz	Received

WED-409	Improved HBV-RNA quantification by HBV-RNA reverse transcription droplet digital PCR	Leen-Jan van Doorn	Received

SAT-409	Whole-genome hepatitis B virus sequencing at low viral loads from serum and dried blood spot using a multiplexed tiled amplicon approach	Sheila Lumley	Received

FRI-409	Enhancing hepatitis delta diagnosis in southern Spain: efficacy and cost-effectiveness of double reflex testing	Federico Garcia Garcia	Received

WED-410	Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort	Miroslava Subic	Received

THU-410	Clinical interventions and use of resources for the management of adverse effects associated with multiple drug interactions in the hepatitis C population	Marinela Mendez	Received

SAT-410	Establishment of a highly effective in vitro model for HBV genotype E infection	Maria Pfefferkorn	Received

FRI-410	Mitochondrial dysfunction and metabolic plasticity in the hepatitis B virus specific immune response: new insights and implications for hepatitis B virus cure	Saima ajaz	Received

WED-411	The large (LHBs) and middle (MHBs) hepatitis B surface antigen are associated with response to bulevirtide or PEG-IFNa treatment in patients with chronic hepatitis Delta (CHD)	Maria Pfefferkorn	Received

FRI-411	Proportions of indeterminate phase of patients with chronic hepatitis B virus infection according to different international guidelines	Shaoqiu Zhang	Received

SAT-411	Absorption, distribution, metabolism, and excretion of [14C]-Bemnifosbuvir in the rats	Alex Vo	Received

THU-411	Long term liver-related events in patients with HCV-related liver disease and advanced fibrosis after sustained virological response with direct-acting antivirals	Jorge Barajas	Received

SAT-412	Low risk of drug-drug interactions for Ruzasvir based upon in vitro metabolism and transporter interaction studies	Alex Vo	Received

THU-412	Hepatitis C lost to follow-up rates in primary care practices in Belgium	Marie Coessens	Received

WED-412	Functional cure and prediction analysis of pegylated interferon alpha-2b in HBeAg negative chronic hepatitis B patients with normal ALT (Ice-breaking Project in China): an interim analysis update	Xiaoguang Dou	Received

FRI-412	Quantification of plasma hdv rna in untreated and bulevirtide-treated patients with chd: a comparison between robogene 2.0, eurobioplex and altostar	Maria Paola Anolli	Received

SAT-413	Hepatitis B virus seroepidemiology in the Vukuzazi population programme, KwaZulu Natal, South Africa	Motswedi Anderson	Received

THU-413	Baseline gamma-glutamyl transpeptidase levels are associated with aggravation of esophagogastric varix after direct-acting antiviral therapy in cirrhotic patients with hepatitis C virus	Yuki Tahata	Received

WED-413	10-year results under tenofovir disoproxil fumarate and entecavir in chronic hepatitis B; HBV clearance rare, disease outcomes good	Zülal &304;stemihan	Received

FRI-413	Prevalence, fate and implication of gray zone on the trajectory of hepatitis B surface antigen in treatment-naïve young adults with chronic hepatitis B infection	Lungyi Mak	Received

SAT-414	Hepatitis B virus particles in serum contain minus strand DNA and degraded pregenomic RNA of variable and inverse lengths	Gustaf Rydell	Received

WED-414	Demographic, virological and clinical features of patients with chronic hepatitis delta treated with bulevirtide: a multicenter italian study (d-shield)	Maria Paola Anolli	Received

FRI-414	Hepatitis B treatment in Africa: experiences from a scale-up program in Ethiopia	Lasse Rossvoll	Received

THU-414	Incidence of hepatocellular carcinoma in patients with hepatitis C treated with direct-acting antivirals agents: results of a long-term prospective study period	Emanuela De Santis	Received

WED-415	Effectiveness and safety analysis of switching to tenofovir alafenamide after entecavir or tenofovir treatment	xuemei Jiang	Received

FRI-415	Hepatitis B virus genotype and some baseline characteristics, but not race, affect HBsAg kinetics during nucleos(t)ide analogue therapy	Rachel Wen-Juei Jeng	Received

SAT-415	Metabolic alteration linked to antiviral treatment response in 3D in-vitro model system of hepatitis B virus infection	Abhishak Chandra Gupta	Received

TOP-416	High frequency of liver cirrhosis in european patients with hepatitis D: first data from a large multicentre study (D-SOLVE and HDV-1000 consortia)	Lisa Sandmann	Received

TOP-417	Machine learning can improve prediction of hepatitis B surface antigen seroclearance: A large multicentre cohort study in the United Kingdom	Tingyan Wang	Received

FRI-418	10-year clinical outcomes in chronic hepatitis B patients treated with tenofovir in The Gambia, West Africa	Erwan Vo Quang	Received

SAT-418	Prevalence of hepatitis C virus infection in a nursing home: a frequently overlooked submerged population	Paolo Gallo	Received

THU-418	Screening for chronic hepatitis C in pre-surgical patients	Mercedes Vergara	Received

WED-418	A national multicenter study on initial antiviral treatment preferences on chronic hepatitis B: Entecavir versus Tenofovir disoproxil fumarate	Tansu Yamazhan	Received

THU-419	Regression of hepatic fibrosis in patients with chronic hepatitis C treated with direct-acting antivirals (DAAs). A long-term, prospective, observational study	Christos Triantos	Received

FRI-419	Epidemiological characteristics of hepatitis D virus infection in patients with hepatitis B related hepatocellular carcinoma	Tangnuer Talafu	Received

SAT-419	Transcriptomics reveals the regulation mechanism of the Chinese herbal TiaoGanJianPiJieDu formula on inhibiting hepatitis B virus replication in mice	Ningyi Zhang	Received

THU-420	Evaluation of LiverRisk score as predictor of liver fibrosis and mortality in patients with HCV-related hepatitis treated with direct acting antivirals	antonietta romano	Received

FRI-420	Serum HBsAg rather than HBV DNA reflects liver HBV transcript levels of hepatitis B patients treated by nucleoside analogues	Feng Ren	Received

SAT-420	The Chinese herbal TiaoGanJianPiJieDu formula exerts an inhibition effect on hepatitis B virus replication by regulating hepatic CCL2-CCR2 signaling pathway and inducing immune-inflammatory response	Ningyi Zhang	Received

WED-420	Evaluation of molnupiravir as an antiviral against hepatitis E virus infection	Siddharth Sridhar	Received

SAT-421	Hepatitis B core related antigen in South Africa and the United Kingdom - does one size fit all?	Louise Downs	Received

WED-422	Screening for viral hepatitis in the emergency department – the methodology to automate a feasible, acceptable and effective solution	Miriam Levy	Received

SAT-422	E-selectin levels in patients with chronic hepatitis C	Petr Husa jr	Received

FRI-423	Early treatment of patients with indeterminate HBV viraemia does not improve retention in care and risks overtreating patients who may spontaneously clear HBsAg	Sharon Macleod	Received

SAT-423	Highly expressed CTLA4 on B cells defected BCR signal to inhibit the secretion of anti-HBs in CHB patients	Shengxia Yin	Received

WED-423	Estimation of the prevalence of hepatitis delta virus infection in the European Union	Hugh Watson	Received

WED-424	Cost-effectiveness of antiviral therapy in patients with chronic hepatitis B in the high viremic gray zone	Suk-Chan Jang	Received

WED-425	Effects of direct-acting antivirals on end-stage liver disease and mortality among Florida Medicaid beneficiaries with chronic hepatitis C	Haesuk Park	Received

SAT-425	Food swamps and easy access to unhealthy food increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) mortality in the United States (U.S.)	Carey Escheik	Received

FRI-426	Comparing the impact of Interferon-based and direct-acting agents therapies on HBsAg seroclearance rates in patients with hepatitis B and hepatitis co-infection	&27491;&20108; &24464;	Received

SAT-426	Prevalence and association between chronic kidney disease and steatotic liver disease in a nationally representative sample in the United States	Mason Lai	Received

WED-426	From kitchen to table: unravelling hepatitis E virus inactivation in pork meat products	Michael Peeters	Received

FRI-427	Chronic hepatitis delta with normal ALT and hepatitis D viremia: unravelling its natural history	Devrim Müge Özar&305; Gülnar	Received

WED-427	Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 – November 2023	Tengiz Tsertsvadze	Received

SAT-427	Hepatocellular carcinoma surveillance in the United Kingdom: a multi-centre study assessing uptake and inequalities	Maria Qurashi	Received

WED-428	Patient, provider, and neighborhood-level factors associated with hepatitis delta testing in an academic health system	Lauren Alpert	Received

SAT-428	Identifying treatment naïve and undiagnosed primary biliary cholangitis patients using a novel case finding database and treatment pathway	Christina Owen	Received

FRI-428	Evaluating the effectiveness and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus	Malipati Aierkenjiang	Received

SAT-429	Impact of body mass index on non-invasive test accuracy for the diagnosis of at-risk metabolic dysfunction-associated steatohepatitis	Cristina Alonso	Received

FRI-429	Detectable HDVRNA is associated with worse outcome in patients infected with HBV and HDV: results from a meta-analysis	Jackie Bitton	Received

WED-429	Hepatitis B virus care cascade in Rwanda: a population based-study	Jean Damascene Makuza	Received

SAT-430	Vaccir study: evaluation of vaccination coverage against diphtheria-tetanus-poliomyelitis, pneumococcus, hepatitis A and B, influenza and SARS-COV2 in cirrhotic patients in 17 french general hospitals	Aurore Baron	Received

WED-430	Epidemiological changes and clinical events in the hepatitis C virus HepCoVe cohort. The viral elimination after availability of novel 20-years observational study	Liliana Chemello	Received

FRI-430	Efficacy and safety of Tenofovir Amibufenamide in the treatment of chronic hepatitis B: a real-world multicenter clinical study	Yaping Li	Received

FRI-431	The underestimated burden of hepatitis D among people living with chronic hepatitis B in the Gambia	Erwan Vo Quang	Received

WED-431	Testing practice and prevalence of hepatitis delta virus (HDV) among patients with chronic hepatitis B (CHB): a large canadian population-based study	Abdel Aziz Shaheen	Received

SAT-431	Exploring liver vitamin A status and histopathological associations in a Guatemalan cohort: insights into prolonged consumption of vitamin A fortified sugar	Giorgio Cazzaniga	Received

WED-432	Systematic review and meta-analysis of barriers and enablers to hepatitis C direct-acting antiviral treatment initiation	Kathleen Bryce	Received

FRI-432	The concentration of HDV-RNA correlates with the probability of developing clinical events in patients with chronic hepatitis D	Adriana Palom	Received

SAT-432	A multi-channel educational communication campaign to improve liver disease screening and awareness for clinical care in Southern Arizona along the United States/Mexico border	David Garcia	Received

SAT-433	Transient elastography identifies previously undiagnosed advanced liver disease among those presenting with alcohol dependence	Rachel Edwards	Received

WED-433	Combatting blood-borne viral syndemics with automated electronic based screenings of HBV, HCV, HDV and HIV in a hospital	Su Wang	Received

FRI-434	High levels of anti-HBc are associated with higher rates of immune control after 48 weeks of treatment with PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B	Maria Pfefferkorn	Received

WED-434	Cost-effectiveness analysis of hepatitis B vaccination policy for newborns in Taiwan	Meng Lun Hsieh	Received

SAT-434	Use of FibroScan® to assess hepatic steatosis and fibrosis in community-based settings to promote clinical care linkages along the Southern Arizona United States/Mexico border	David Garcia	Received

FRI-435	Serological and nucleic acid testing laboratory screening rates for hepatitis delta virus among adult patients in the United States	Chong Kim	Received

SAT-435	Benefits and harms of post-treatment surveillance in patients with early-stage of HCC after curative ablation	Awassada Yangcharoen	Received

WED-435	Prevalence of active hepatitis delta infection among new diagnoses of hepatitis B in the Barcelona metropolitan area	Cortese Francesca	Received

SAT-436	Age and sex differences in the incidence of cirrhosis caused by metabolic dysfunction associated steatohepatitis in Manitoba, Canada: a population-based study	Nabiha Faisal	Received

FRI-436	Are healthcare professionals appropriately screening for hepatitis delta virus in patients with chronic hepatitis B? Results from an interactive decision support app	Sarah Anderson	Received

WED-436	HCV reinfection among people who use drugs (PWUD) treated for HCV infection: a long-term view	Rossitta Yung	Received

FRI-437	Poor Performance of FIB-4 in Fibrosis Prediction for Chronic Hepatitis B Patients with Metabolic Dysfunction–Associated Liver Disease in Daily Clinical Practice	Fadi Abu Baker	Received